var title_f4_15_4336="Thumb spica cast 1";
var content_f4_15_4336=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F74904&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F74904&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thumb spica cast: Step 1",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    First, place a piece of stockinette or similar material over the thumb.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin E Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_15_4336=[""].join("\n");
var outline_f4_15_4336=null;
var title_f4_15_4337="Pseudomembranous colitis Gross";
var content_f4_15_4337=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F62422&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F62422&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pseudomembranous colitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 398px; height: 247px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gross appearance of the colon from a patient with pseudomembranous colitis. The pseudomembranes are yellow or off-white raised plaques 0.2 to 2.0 cm in diameter, which are scattered over fairly normal-appearing intervening mucosa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of J Thomas LaMont, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_15_4337=[""].join("\n");
var outline_f4_15_4337=null;
var title_f4_15_4338="Rhinosinusitis computed tomography";
var content_f4_15_4338=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F84006&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F84006&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Computed tomography findings in rhinosinusitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 399px; height: 512px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computed tomography (CT)&nbsp;findings in rhinosinusitis:",
"    <br>",
"     (A) Coronal CT demonstrating complete opacification of the right ethmoid sinus (white arrow) and mucosal thickening of the roof of the right maxillary sinus (yellow arrow).",
"     <br>",
"      (B) Axial CT demonstrating air-fluid level (white arrow) in the right maxillary sinus.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Courtesy of Glenn C Isaacson, MD, FAAP, FACS.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_15_4338=[""].join("\n");
var outline_f4_15_4338=null;
var title_f4_15_4339="Stockinette short arm";
var content_f4_15_4339=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F50511&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F50511&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Stockinette for a short arm cast",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 355px; height: 468px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Stockinette is the first layer of any cast. Take care to avoid wrinkles, which can contribute to pressure lesions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen Titus, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_15_4339=[""].join("\n");
var outline_f4_15_4339=null;
var title_f4_15_4340="Fibroid embolization PI";
var content_f4_15_4340=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F86790&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F86790&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 572px\">",
"   <div class=\"ttl\">",
"    Uterine artery embolization",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 552px; height: 464px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     During a uterine artery embolization, a doctor inserts a thin tube called a \"catheter\" into the &ldquo;femoral artery&rdquo; at the top of 1 leg. Then he or she advances the tube until the tip of the tube reaches a smaller artery on the other side of the body, called the &ldquo;uterine artery,&rdquo; which carries blood to the uterus (on left). Next the doctor injects a special dye that can be seen on X-rays. The dye allows the doctor to see which arteries bring blood to the fibroid. Next, the doctor injects tiny plastic beads into those arteries to block the flow of blood (see panel on right). This cuts off the blood supply to the fibroid, which causes the fibroid to shrink.",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_15_4340=[""].join("\n");
var outline_f4_15_4340=null;
var title_f4_15_4341="Gadoteridol: Drug information";
var content_f4_15_4341=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Gadoteridol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?27/38/28259?source=see_link\">",
"    see \"Gadoteridol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F175126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      ProHance&reg;;",
"     </li>",
"     <li>",
"      ProHance&reg; Multipack&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F175129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Diagnostic Agent;",
"     </li>",
"     <li>",
"      Gadolinium-Containing Contrast Agent;",
"     </li>",
"     <li>",
"      Radiological/Contrast Media (Nonionic, Low Osmolality);",
"     </li>",
"     <li>",
"      Radiological/Contrast Media, Paramagnetic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F3410029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS imaging: I.V.: 0.1 mmol/kg (0.2 mL/kg); if needed, a second dose of 0.2 mmol/kg (0.4 mL/kg) may be repeated once within 30 minutes of the first dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Extracranial/extraspinal tissue: I.V.: 0.1 mmol/kg (0.2 mL/kg)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F3410028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CNS imaging: I.V.: Children &ge;2 years: 0.1 mmol/kg (0.2 mL/kg)",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F3410030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose adjustment is not recommended; however, use with caution. Risk for NSF development increases as renal function decreases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hemodialysis: If administered to patients already receiving hemodialysis, consider prompt hemodialysis following exposure (eg, within 3 hours) (Kuo, 2007). Data has been shown hemodialysis enhances gadolinium elimination with average gadolinium excretory rates of 78%, 96%, and 99% in the first, second, and third hemodialysis sessions, respectively (Kuo, 2007; Okada, 2001).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peritoneal dialysis: Likely to be less efficient at clearing gadolinium (Joffe, 1998; Kuo, 2007).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F3410031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution; safety and efficacy have not been studied.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F175121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ProHance&reg;: 279.3 mg/mL (5 mL, 10 mL, 15 mL, 17 mL, 20 mL) [contains natural rubber/natural latex in prefilled syringe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ProHance&reg; Multipack&trade;: 279.3 mg/mL (50 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F175118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F3410032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer as a rapid infusion (10-60 mL/minute) or as a bolus (&gt;60 mL/minute). Flush line with NS 5 mL to ensure complete injection of medium. Imaging should be completed within 60 minutes of injection.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F175122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contrast medium for magnetic resonance imaging (MRI) to visualize CNS lesions with abnormal vascularity in the brain, spine, and associated tissues and to visualize extracranial/extraspinal tissues in the head and neck",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F12931886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contrast medium for magnetic resonance angiography (MRA)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5174543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F3410011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%: Gastrointestinal: Nausea (1%), taste perversion (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1%, postmarketing, and/or case reports (Limited to important or life-threatening): Abdominal cramps, anaphylactoid reaction, anxiety, apnea, A-V nodal rhythm, bradycardia, cardiac arrest, chest pain, coordination loss, cough, cyanosis, deafness (transient), diaphoresis, diarrhea, dizziness, dysphagia, dyspnea, edema, facial edema, fever, flushing, gingivitis, headache, heart rate increased, hives, hyper/ hypotension, injection site pain/reactions, itching, laryngeal edema, laryngismus, loss of consciousness, macular papular rash, malaise, mental status decline, neck rigidity; nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy (NSF/NFD); pain, paresthesia, P-R interval prolonged, pruritus, rash, rhinitis, salivation increased, seizure, staring episode, stupor, syncope, tingling sensations, tinnitus, tongue edema/itching, tremor, urinary incontinence, urticaria, vasovagal reaction, voice alteration, vomiting, watery eyes, wheezing, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F3410006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any gadolinium-based contrast agent",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F3410007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Hypersensitivity, including anaphylactic reactions (rare), may occur; appropriate equipment (eg, ventilator) and emergency medications (eg, epinephrine) should be available during use. Delayed reactions may also occur (within several hours of administration). Patients with a history of allergic reactions and/or bronchial asthma may be at an increased risk for developing hypersensitivity reactions; use caution in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nephrogenic systemic fibrosis:",
"     <b>",
"      [U.S. Boxed Warning]: Gadolinium-based contrast agents (GBCAs) exposure may increase the risk for nephrogenic systemic fibrosis (NSF) in patients with renal impairment; avoid use unless GBCA enhanced imaging is essential for diagnostic purposes. The risk is highest in patients with acute kidney injury or chronic, severe renal disease (GFR &lt;30 mL/minute/1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      ).",
"     </b>",
"     The risk appears lower in patients with moderate, chronic renal disease (GFR 30-59 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ) and little, if any, in patients with mild, chronic renal disease (GFR 60-89 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ). NSF, a potentially fatal disease, affects the skin, muscle, and internal organs and can occur days to months after exposure. All patients should be screened for renal dysfunction prior to administration; estimate GFR in patients at risk for chronic renal disease (diabetes, hypertension, age &gt;60 years). In patients at risk of NSF, do not exceed the recommended dosage and allow sufficient time (ie, several half-lives) for elimination prior to readministration (avoidance of readministration is preferred). In patients receiving hemodialysis, consider prompt initiation of hemodialysis following administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment. Dose-dependent worsening of renal function or acute renal failure has occurred in patients with renal insufficiency following use of other gadolinium agents, generally within 48 hours following administration. Evaluate renal function in patients with renal impairment prior to use; consider follow-up monitoring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sickle cell anemia: In",
"     <i>",
"      in vitro",
"     </i>",
"     studies, deoxygenated sickle erythrocytes align perpendicular to a magnetic field; the enhancement of magnetic moment by contrast agents may potentiate this alignment possibly resulting in vaso-occlusive complications",
"     <i>",
"      in vivo",
"     </i>",
"     . Use in patients with sickle cell anemia or other hemoglobinopathies has not been studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Repeat doses: Repeated procedures have not been studied; safety of sequential doses has only been studied in adults in central nervous system during the same diagnostic session.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F5563034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Contrast Media (Non-ionic) may enhance the potential for allergic or hypersensitivity reactions to Aldesleukin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F175119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F175124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies. Gadolinium-based contrast agents cross the placenta in humans. Gadolinium-based agents should not routinely be administered to pregnant women (Expert Panel on MR Safety, 2013; Wang, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F175127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16353415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Gadolinium-based contrast agents are excreted in breast milk in small amounts and oral absorption is poor; information specific to gadoteridol is not available. Although some sources state breast-feeding may be continued, the manufacturer recommends caution be used if administered to nursing women. Contrast media may temporarily alter the taste of breast milk (Tremblay, 2012; Webb, 2005).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Prohance Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     279.3 mg/mL (10 mL): $69.80",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F3410035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs of hypersensitivity (during and for several hours after procedure); renal function (prior to administration); short- and long-term monitoring of signs and symptoms of NSF (eg, burning, itching, swelling, hardening and/or tightening of skin, joint stiffness, deep hip or rib bone pain, muscle weakness, limited range of motion, and/or yellowed/raised spots on whites of eye)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F175125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      ProHance (AT, AU, BE, CH, CZ, DE, DK, FI, FR, GB, IE, IT, NL, NO, PL, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F3410020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Gadoteridol is a gadolinium-containing paramagnetic agent. Exposure to an external magnetic field induces a large local magnetic field in exposed tissues. This local magnetism disrupts water protons in the vicinity, resulting in a change in proton density and spin characteristics, which can be detected by the imaging device.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F3410022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 204 &plusmn; 58 mL/kg; does not cross intact blood-brain barrier; distribution half-life: 0.2 &plusmn; 0.04 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 1.57 &plusmn; 0.08 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (~94%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control, &ldquo;Nephrogenic Fibrosing Dermopathy Associated with Exposure to Gadolinium-Containing Contrast Agents: St. Louis, Missouri,&rdquo;",
"      <i>",
"       MMWR Weekly Rep",
"      </i>",
"      , 2007, 56(07):137-141.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Expert Panel on MR Safety, \"ACR Guidance Document on MR Safe Practices: 2013,\"",
"      <i>",
"       J Magn Reson Imaging",
"      </i>",
"      , 2013, 37(3):501-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/15/4341/abstract-text/23345200/pubmed\" id=\"23345200\" target=\"_blank\">",
"        23345200",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grobner T, &ldquo;Gadolinium - A Specific Trigger for the Development of Nephrogenic Fibrosing Dermopathy and Nephrogenic Systemic Fibrosis,&rdquo;",
"      <i>",
"       Nephrol Dial Transplant",
"      </i>",
"      , 2006, 21(4):1104-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/15/4341/abstract-text/16431890/pubmed\" id=\"16431890\" target=\"_blank\">",
"        16431890",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Joffe P, Thomsen HS, and Meusel M, \"Pharmacokinetics of Gadodiamide Injection in Patients with Severe Renal Insufficiency and Patients Undergoing Hemodialysis or Continuous Ambulatory Peritoneal Dialysis,\"",
"      <i>",
"       Acad Radiol",
"      </i>",
"      , 1998, 5(7):491-502.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/15/4341/abstract-text/9653466/pubmed\" id=\"9653466\" target=\"_blank\">",
"        9653466",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kuo PH, Kanal E, Abu-Alfa AK, et al, \"Gadolinium-Based MR Contrast Agents and Nephrogenic Systemic Fibrosis,\"",
"      <i>",
"       Radiology",
"      </i>",
"      , 2007, 242(3):647-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/15/4341/abstract-text/17213364/pubmed\" id=\"17213364\" target=\"_blank\">",
"        17213364",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Okada S, Katagiri K, Kumazaki T, et al, &ldquo;Safety of Gadolinium Contrast Agent in Hemodialysis Patients,&rdquo;",
"      <i>",
"       Acta Radiol",
"      </i>",
"      , 2001, 42(3):339-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/15/4341/abstract-text/11350296/pubmed\" id=\"11350296\" target=\"_blank\">",
"        11350296",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tremblay E, Th&eacute;rasse E, Thomassin-Naggara I, et al, \"Quality Initiatives: Guidelines for Use of Medical Imaging During Pregnancy and Lactation,\"",
"      <i>",
"       Radiographics",
"      </i>",
"      , 2012, 32(3):897-911.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/15/4341/abstract-text/22403117/pubmed\" id=\"22403117\" target=\"_blank\">",
"        22403117",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wang PI, Chong ST, Kielar AZ, et al, \"Imaging of Pregnant and Lactating Patients: Part 1, Evidence-Based Review and Recommendations,\"",
"      <i>",
"       AJR Am J Roentgenol",
"      </i>",
"      , 2012, 198(4):778-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/15/4341/abstract-text/22451541/pubmed\" id=\"22451541\" target=\"_blank\">",
"        22451541",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Webb JA, Thomsen HS, and Morcos SK, \"The Use of Iodinated and Gadolinium Contrast Media During Pregnancy and Lactation,\"",
"      <i>",
"       Eur Radiol",
"      </i>",
"      , 2005, 15(6):1234-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/15/4341/abstract-text/15609057/pubmed\" id=\"15609057\" target=\"_blank\">",
"        15609057",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Widmark JM, &ldquo;Imaging-related Medications: A Class Overview,&rdquo;",
"      <i>",
"       Proc(Bayl Univ Med Cent)",
"      </i>",
"      , 2007, 20(4):408-17.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8886 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-AB43D6AFE1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_15_4341=[""].join("\n");
var outline_f4_15_4341=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708886\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175126\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175129\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3410029\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3410028\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3410030\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3410031\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175121\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175118\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3410032\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175122\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12931886\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5174543\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3410011\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3410006\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3410007\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299380\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5563034\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175119\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175124\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175127\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16353415\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323165\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3410035\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175125\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3410020\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3410022\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8886\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8886|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?27/38/28259?source=related_link\">",
"      Gadoteridol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_15_4342="Endstage sarcoidosis PA";
var content_f4_15_4342=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80390&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80390&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endstage sarcoidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 348px; height: 347px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph shows a destructive pattern with marked loss of volume in both upper lobes, retraction of both hilar regions cephalad, distortion, and hyperexpansion of the lung bases. Bilateral upper lobe cavities containing mycetomas are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_15_4342=[""].join("\n");
var outline_f4_15_4342=null;
var title_f4_15_4343="MPS I cord compression A";
var content_f4_15_4343=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58332%7EPEDS%2F72193&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58332%7EPEDS%2F72193&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Spinal cord compression in a patient with mucopolysaccharidosis type I (MPS I, Hurler-Scheie syndrome) A",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 256px; height: 398px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A sagittal T2-weighted MR image of the spine in a 25-year-old with Hurler-Scheie syndrome and spinal cord compression, making him unable to walk. Little or no CSF (white) is anterior to the cord (gray) in the thoracic and cervical region. In the upper cervical region, CSF is completely excluded by meningeal thickening, which also compresses the cord.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Emil Kakkis, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Spinal cord compressions in a patient with mucopolysaccharidosis type I (MPS I, Hurler-Scheie syndrome) B",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 256px; height: 403px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A sagittal T1-weighted MR image of the cervical spine in a patient with Hurler-Scheie syndrome showing the grossly abnormal vertebrae and intervertebral discs. Note the abnormal spinus processes of the upper cervical vertebrae and constriction of the cord due to soft tissue thickening and meningeal storage. An enlarged cisterna magna with small cerebellum is also evident.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Emil Kakkis, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_15_4343=[""].join("\n");
var outline_f4_15_4343=null;
var title_f4_15_4344="Pathophysiology of left to right shunts";
var content_f4_15_4344=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathophysiology of left to right shunts",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/15/4344/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/15/4344/contributors\">",
"     Grace C Kung, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/15/4344/contributors\">",
"     John K Triedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/15/4344/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/15/4344/contributors\">",
"     David R Fulton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/15/4344/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/15/4344/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/15/4344/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In conditions with left-to-right shunt, blood from the systemic arterial circulation mixes with systemic venous blood. Multiple factors influence the extent of flow through the shunt and its physiologic effects.",
"   </p>",
"   <p>",
"    The pathophysiology of left-to-right shunts is reviewed here. The evaluation and management of specific cardiac lesions are discussed separately. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FETAL AND TRANSITIONAL CIRCULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the fetus, oxygenated blood is delivered from the placenta via the umbilical vein, which traverses through the liver via the ductus venosus to join the inferior vena cava (IVC) (",
"    <a class=\"graphic graphic_figure graphicRef66765 \" href=\"UTD.htm?14/43/15032\">",
"     figure 1",
"    </a>",
"    ). Approximately 45 percent of the umbilical venous blood enters the portal venous system and perfuses the liver en route to the right atrium, while the remainder enters the right atrium directly. This oxygenated umbilical venous blood, which enters the right atrium from the IVC, is preferentially directed across the patent foramen ovale to the left atrium and ventricle. This provides the coronary circulation and arteries supplying the head and neck with relatively well-oxygenated blood.",
"   </p>",
"   <p>",
"    Blood returning through the superior vena cava is more likely to cross the tricuspid valve, and is ejected via the main pulmonary artery to the lungs or through the ductus arteriosus into the descending aorta. Overall, most of the blood exiting the right ventricle passes right-to-left across the ductus, with only 8 to 10 percent of the fetal cardiac output perfusing the lungs. This distribution of flow is favored by the constriction of the pulmonary arterial bed, resulting in a high pulmonary vascular resistance (PVR), and by the low vascular resistance in the placenta, which results in low systemic vascular resistance (SVR).",
"   </p>",
"   <p>",
"    With the onset of respiration after delivery, the lungs expand and systemic oxygenation rises. This results in pulmonary vasodilatation and a drop in PVR [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4344/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. At the same time, ligation of the umbilical cord removes the placenta from the circulation, with a subsequent increase in SVR. The net impact of these changes is a sudden reversal of blood flow in the ductus from the aorta to the pulmonary artery. In general, increased arterial oxygenation at the ductus results in its constriction and subsequent permanent closure. In addition, the increased pulmonary blood flow, associated with increased pulmonary venous return to the left atrium, usually results in simultaneous functional closure of the foramen ovale. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/19/8502?source=see_link\">",
"     \"Physiologic transition from intrauterine to extrauterine life\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As PVR falls, pulmonary artery pressure declines to approximately one-half systemic levels within 24 hours of birth. In the six to eight weeks after birth, PVR continues to decrease as the smooth muscle layer in the pulmonary vasculature becomes thinner. Pulmonary artery pressure becomes close to adult levels during this period.",
"   </p>",
"   <p>",
"    In the normal infant, following the postnatal period of transitional circulation and closure of the ductus arteriosus and foramen ovale, no communication exists between the systemic arterial (left side) and pulmonary (right side) systems. Systemic venous return is directed to the lungs for oxygenation and returns to the left side to be directed toward the body.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;When an abnormal connection exists between the systemic and pulmonary circulations, the potential exists for an excess volume of blood to flow from the systemic (left side) circulation to the pulmonary circulation (right side). These connections include intracardiac defects such as atrial and ventricular septal defects, and vascular connections such as patent ductus arteriosus (PDA) and arteriovenous fistulae. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/52/35656?source=see_link\">",
"     \"Clinical manifestations and diagnosis of patent ductus arteriosus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/50/15145?source=see_link\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of patent ductus arteriosus in premature infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Shunt size",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extent of extra flow is assessed as the ratio of measured pulmonary blood flow (Qp) to systemic blood flow (Qs). In the normal case, where no connection exists, the ratio Qp:Qs is 1:1. Left-to-right shunting results in a Qp:Qs &gt;1, while right-to-left shunting results in a Qp:Qs &lt;1. For example, a Qp:Qs of 2:1 indicates that the pulmonary blood flow is twice that of systemic blood flow.",
"   </p>",
"   <p>",
"    The overall effect of a left-to-right shunt is the recirculation of already oxygenated pulmonary venous blood through the pulmonary vasculature. This excess pulmonary blood flow results directly or indirectly in almost all of the significant clinical features that characterize heart failure in infants and children.",
"   </p>",
"   <p>",
"    The pathophysiologic changes that occur depend upon the size of the shunt, which is a measure of the excess volume of pulmonary blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4344/abstract/3\">",
"     3",
"    </a>",
"    ]. Factors that affect the size of the shunt include the location of the anatomic communication, its size, the age of the patient, and the relative resistances to blood flow on either side of the communication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pulmonary effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung mechanics are often abnormal in children with large left-to-right shunts and increased pulmonary blood flow. In one study, for example, tidal volume and lung compliance were lower and expiratory airway resistance was higher in infants with congenital heart disease and left-to-right shunts than in healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4344/abstract/4\">",
"     4",
"    </a>",
"    ]. Decreased lung compliance may be exacerbated in patients who also have elevated pulmonary artery pressure.",
"   </p>",
"   <p>",
"    The mechanism of abnormal pulmonary mechanics is thought to be due to increased extravascular lung water, which appears to be directly related to the increase in Qp. The increased extravascular lung water results from transudation of fluid under increased pressure across capillary walls at rates greater than can be accommodated by lymphatic drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4344/abstract/5\">",
"     5",
"    </a>",
"    ]. If Qp and pulmonary venous pressure are extremely elevated, transudation of fluid into the lungs may result in clinical and radiographic findings of pulmonary edema, although this is uncommon. Pulmonary function abnormalities resolve after surgical repair and normalization of Qp [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4344/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Neurohumoral activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sympathetic nervous system and the renin-angiotensin system are highly activated in patients with left-to-right shunts [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4344/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. In one report of children with noncyanotic congenital heart disease, plasma norepinephrine (NE) concentration was higher and lymphocyte beta-adrenergic receptor density was lower in those with than without heart failure; epinephrine concentration was similar [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4344/abstract/7\">",
"     7",
"    </a>",
"    ]. The extent of left-to-right shunt flow and pulmonary systolic pressure was directly related to plasma NE concentration and indirectly related to beta-adrenergic density. In another study of infants with left-to-right shunts, NE concentration and plasma renin activity were more closely associated with clinical signs of heart failure, such as tachypnea, than conventional hemodynamic measurements of the volume of shunting, such as Qp:Qs [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4344/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cardiac hormone B-type natriuretic peptide (BNP), which has diuretic and vasodilatory properties, is increased in congenital heart disease, as well as a variety of other cardiac conditions. A study comparing BNP values of a group of patients with congenital heart disease to normal controls showed that patients with a significant left-to-right shunt had increased levels of BNP, with the increase positively correlated with shunt volume [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4344/abstract/9\">",
"     9",
"    </a>",
"    ] In another study, preterm and full term neonates with significant left-to-right shunts (due to either intracardiac septal defect or patent ductus arteriosus), had higher BNP levels compared with patients who underwent cardiac evaluation but did not have significant left-to-right shunts [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4344/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Metabolic effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute and chronic malnutrition are common in children with heart failure, occurring in 60 percent of hospitalized children with left-to-right shunts [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4344/abstract/11\">",
"     11",
"    </a>",
"    ]. The mechanism for poor growth is uncertain, but appears to be due to elevated metabolic expenditures associated with increased respiratory effort and myocardial work, leading to decreased nutritional intake",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increased catabolism. The latter is supported by measurements of increased oxygen consumption in infants with large left-to-right shunts that became normal after surgical correction of the cardiac lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4344/abstract/12\">",
"     12",
"    </a>",
"    ]. In another study, reduced protein or energy intake did not appear to be the primary cause of inadequate growth [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4344/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pulmonary hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increased pulmonary blood flow caused by left-to-right shunting often is associated with sustained elevation of pulmonary artery pressure, sometimes at systemic levels. This results from failure of the pulmonary microvasculature to undergo the normal remodeling of the pulmonary arteriolar wall that occurs in early infancy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4344/abstract/14\">",
"     14",
"    </a>",
"    ]. Alveolar hypoxia or other local effects that favor pulmonary vasoconstriction may exacerbate this process. Initially, there is overgrowth of vascular smooth muscle as well as intimal proliferation, causing gradual effacement of the pulmonary arterioles. These changes lead to loss of the normal reactivity of the pulmonary vascular bed and ultimately result in fixed pulmonary hypertension and irreversible pulmonary vascular disease.",
"   </p>",
"   <p>",
"    The resulting increased pulmonary vascular resistance may reduce the amount of left-to-right shunt and partly ameliorate signs of heart failure. However, this insidious process ultimately results in permanent injury to the pulmonary vasculature.",
"   </p>",
"   <p>",
"    Abnormalities of local vascular signaling and impaired endothelial function may be important in vascular remodeling and the development of pulmonary hypertension. This is supported by the demonstration of increased concentration of plasma endothelin, a pulmonary vasoconstrictor [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4344/abstract/15\">",
"     15",
"    </a>",
"    ], and impaired endothelium-dependent pulmonary vascular relaxation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4344/abstract/16\">",
"     16",
"    </a>",
"    ] in patients with increased pulmonary blood flow due to left-to right shunts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with increased pulmonary blood flow due to left-to-right shunting can be asymptomatic or have tachypnea or respiratory distress. In general, left-to-right shunts with Qp:Qs &gt;2:1 have significant hemodynamic consequences.",
"   </p>",
"   <p>",
"    Typical clinical manifestations of left-to-right shunting include [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4344/abstract/8,17,18\">",
"     8,17,18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tachypnea due to interstitial edema",
"     </li>",
"     <li>",
"      Tachycardia and diaphoresis due to increased release of catecholamines from the adrenal glands and myocardium",
"     </li>",
"     <li>",
"      Poor weight gain resulting from increased caloric demands and myocardial oxygen demands",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Affected patients also may develop hepatomegaly.",
"   </p>",
"   <p>",
"    The clinical manifestations and severity of heart failure were examined in a study of 41 infants (median age 2.5 months) with congenital heart disease who were evaluated by pediatric cardiologists [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4344/abstract/19\">",
"     19",
"    </a>",
"    ]. The most sensitive and specific signs and symptoms of heart failure were a history of poor feeding (&lt;3.5",
"    <span class=\"nowrap\">",
"     ounces/feed),",
"    </span>",
"    tachypnea (respiratory rate",
"    <span class=\"nowrap\">",
"     &gt;50/min),",
"    </span>",
"    an audible gallop, and hepatomegaly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Respiratory effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory distress is the most prominent sign of heart failure caused by significant left-to-right shunting in infancy. Decreased pulmonary compliance due to increased interstitial lung water results in increased work of breathing, which is manifested as tachypnea, flaring of the nasal alae, and intercostal retractions. Frank pulmonary edema is uncommon. Excessive pulmonary blood flow may also result in compromise of airways, leading to atelectasis and emphysema. Ventilatory limitations may result in poor feeding. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Pathophysiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pulmonary infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with large left-to-right shunts have increased vulnerability to viral infections that affect the lower respiratory tract, especially respiratory syncytial virus (RSV). In these patients, RSV infection is associated with increased mortality and prolonged hospitalization, compared with unaffected children [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4344/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7050?source=see_link\">",
"     \"Respiratory syncytial virus infection: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Poor growth",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increased work of breathing combined with poor intake contribute to poor growth in infants, even when caloric intake appears adequate. Growth may be affected even when the shunt is small and patients are otherwise asymptomatic. In one study, growth significantly improved following repair of isolated secundum atrial septal defect in children with mild failure to thrive [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4344/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Time of presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because pulmonary vascular resistance (PVR) is elevated, little left-to-right shunting occurs immediately after birth in term newborns, even those with large communications due to ventricular septal defects or patent ductus arteriosus (PDA). Shunting usually increases as PVR declines during the first postnatal weeks. Clinical manifestations may develop as shunting increases.",
"   </p>",
"   <p>",
"    Infants tolerate the increased circulating volume poorly compared with older children. This is due in part to their limited capacity to adjust stroke volume in response to increased metabolic demands.",
"   </p>",
"   <p>",
"    Symptoms may be exacerbated by anemia because oxygen carrying capacity is reduced and cardiac output increases. In contrast, the increased viscosity associated with higher hemoglobin concentration may slightly elevate PVR and decrease shunting [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4344/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In premature infants, PVR decreases more rapidly and accelerates the time course for development of left-to-right shunting through a PDA. The resulting excessive flow through the pulmonary circulation frequently causes pulmonary edema, leading to a need for increased ventilatory support and signs of decreased systemic perfusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/50/15145?source=see_link\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of patent ductus arteriosus in premature infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CAUSES OF SHUNTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left-to-right shunting can occur due to communications at the atrial, ventricular, and arterial level, which is usually due to a difference in the resistances of each circuit with blood preferentially shunting from a higher to lower resistance circulation. Shunting at each level results in specific pathophysiologic and clinical effects. The different effects result from differences in the downstream resistance to flow on either side of the communication as well as instantaneous differences in the pressures measured in the chambers on either side of the communication during systole and diastole.",
"   </p>",
"   <p>",
"    Examples of left-to-right shunts occurring at each level are atrial septal defect (ASD, atrial level), ventricular septal defect (VSD, ventricular level) and patent ductus arteriosus (PDA, level of the great arteries). Shunts frequently occur at more than one level in the same patient. For example, an infant may have atrial and ventricular septal defects and a PDA.",
"   </p>",
"   <p>",
"    Other types of left-to-right shunts do not clearly fit into these categories, but their physiologic effects most resemble atrial level shunts. These involve connections between the systemic arterial circulation and a lower resistance system other than the pulmonary vasculature. Examples are hepatic or cerebral arteriovenous malformations, and surgically created arteriovenous fistulae.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Atrial level shunts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lesions at the atrial level that cause left-to-right shunting include ASDs of all types and anomalous pulmonary venous drainage. The principal determinant of shunting at this level is the relative compliance of the right and left ventricles. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26201?source=see_link\">",
"     \"Classification and clinical features of isolated atrial septal defects in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/32/3593?source=see_link\">",
"     \"Patent foramen ovale\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/36/3656?source=see_link\">",
"     \"Partial anomalous pulmonary venous connection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/51/10040?source=see_link\">",
"     \"Total anomalous pulmonary venous connection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The atria normally fill throughout the cardiac cycle by venous return from the systemic and pulmonary veins, and empty into the ventricles through the tricuspid and mitral valves during ventricular diastole. The right ventricle is normally much thinner-walled and more compliant than the thick-walled left ventricle. As a result, blood flows preferentially through the tricuspid valve during diastole. In the presence of an ASD, the more rapid emptying of the right atrium results in left-to-right shunting. The increased pulmonary venous return to the left atrium further favors left-to-right shunting across the atrial communication.",
"   </p>",
"   <p>",
"    Atrial level shunts often result in enlargement of the right ventricle, which is known as right ventricular volume overload. This finding may be suggested by the electrocardiogram or visualized by echocardiogram. Hormonal measures such as B-type natriuretic peptide (BNP) may be elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4344/abstract/23\">",
"     23",
"    </a>",
"    ]. However, although Qp is increased, it is rare that right ventricular and pulmonary artery pressures are significantly elevated. Exceptions to this occur, such as the concomitant presence of other, more significant intracardiac or vascular lesions that themselves cause increased right ventricular",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pulmonary artery pressures.",
"   </p>",
"   <p>",
"    Because left-to-right shunting at the atrial level is primarily dependent upon the diastolic properties of the right ventricle, elevation of systolic right ventricular pressure has little immediate effect on such shunts. However, when elevated right ventricular systolic pressure results in significant hypertrophy of the right ventricle, diastolic compliance may decrease, limiting the volume of shunt.",
"   </p>",
"   <p>",
"    An exception to the dependence of shunting on relative ventricular compliance is when the ASD is very small. In this case, the size of the defect itself may limit flow. The left-to-right flow in such very small defects is rarely of clinical significance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Newborns",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newborns with ASDs may have right-to-left shunting. This is due to hypertrophy and decreased diastolic compliance of the right ventricle at birth, resulting from exposure to systemic pressures during fetal development. As pulmonary vascular resistance (PVR) gradually declines postnatally, right ventricular compliance slowly increases and is accompanied by increasing atrial left-to-right shunting. Thus, most infants with ASDs do not present early. An exception is the infant with an ASD who also has obstruction of the mitral valve. In this case, resistance to left ventricular filling is so impaired that blood is forced left-to-right across the defect to fill the right ventricle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Ventricular level shunts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular level shunts result from all types of VSDs, including membranous and muscular defects, AV canal, and conoventricular defects. The pathophysiologic changes associated with a VSD depend upon the size of the defect and the resistance to flow distal to the lesion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/19/8506?source=see_link&amp;anchor=H7#H7\">",
"     \"Pathophysiology and clinical features of isolated ventricular septal defects in infants and children\", section on 'Pathophysiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/52/14154?source=see_link\">",
"     \"Ventricular septal defect in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13752?source=see_link\">",
"     \"Pathophysiology, clinical features, and diagnosis of tetralogy of Fallot\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As noted above, left-to-right shunts at the atrial level lead to isolated increases in right ventricular and pulmonary blood flow; pressures are usually normal. Additional consequences of shunts at the ventricular level are",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased pulmonary blood flow originates from the left as well as the right ventricle. This left ventricular volume overload may result in hypertrophy and increased end-diastolic pressure, which in turn may cause increased pulmonary venous pressure.",
"     </li>",
"     <li>",
"      Unrestrictive VSDs often result in significant pulmonary hypertension, with pulmonary arteries facing systemic or near systemic pressures.",
"     </li>",
"     <li>",
"      Recirculation of blood from the left ventricle to the pulmonary circulation occurs at the expense of some systemic blood flow. These may result in the initiation of compensatory reflex mechanisms to maintain organ perfusion which have deleterious long-term effects.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The size of the defect influences its effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Small VSDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small VSDs restrict left-to-right shunting by providing direct resistance to flow. In general, they limit the systolic pressure of the right ventricle to normal or near-normal levels. Their pathophysiologic effects are also minor. They usually result in a small left-to-right shunt, with normal PVR, normal pulmonary artery and right ventricular pressures, and little increase in ventricular stroke work. Symptoms and signs of heart failure are rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Moderate VSDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;In moderate-sized VSDs, some limitation of shunting occurs. However, if PVR is low, a significant left-to-right shunt may develop. This results in volume overload of the left atrium and ventricle and signs and symptoms of heart failure. In these patients, PVR, right ventricular pressures, and pulmonary artery pressures may remain low or be moderately elevated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Large VSDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large VSDs are unrestrictive; ie, they provide no effective resistance to flow between the right and left ventricles. As a result, pressures in the two ventricles are approximately equal throughout the cardiac cycle, and the overall amount of left-to-right shunt is dependent upon the resistance of the pulmonary and systemic vascular beds.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h4\">",
"     Associated lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Associated stenotic lesions of the right",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    left ventricular outflow tracts modify the flow across a large VSD. For example, tetralogy of Fallot typically includes a large, unrestrictive VSD caused by malalignment of two components of the ventricular septum. However, the amount of left-to-right shunting in this disorder is determined by the degree of obstruction of the right ventricular outflow tract.",
"   </p>",
"   <p>",
"    Other examples of anatomic obstruction to flow include valvar or supravalvar pulmonic stenosis, hypoplasia of the pulmonary arteries, decreased cross-sectional area of the pulmonary vascular distribution or pulmonary arteriolar changes. Obstruction to left ventricular outflow, such as subvalvar and valvar aortic stenosis or obstructive lesions of the aortic arch, favor left-to-right shunting. In addition, the physiologic anemia that develops during the first two to three months after birth exacerbates the fall in PVR, increasing left-to-right shunting.",
"   </p>",
"   <p>",
"    In the presence of large defects, the normal postnatal decline in PVR may be delayed for several months. This reduces the extent of left-to-right shunting and limits the development of left ventricular volume overload and signs and symptoms of heart failure. Thus, newborns with large VSDs may sometimes have a relatively symptom-free (\"honeymoon\") period before PVR falls. However, as PVR decreases, pulmonary blood flow increases, leading to left atrial and ventricular volume overload. As left ventricular and left atrial pressures rise, pulmonary venous hypertension develops, contributing to pulmonary edema and diminished pulmonary compliance. Paradoxically, the absence of signs of heart failure in an infant with a large VSD may be an ominous sign, as it may suggest the early development of irreversible pulmonary vascular disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h4\">",
"     Changes during cardiac cycle",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree and direction of shunting through a large VSD varies during the cardiac cycle:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Left-to-right shunting across the defect mostly occurs during systole, and is determined by the relative pulmonary and systemic vascular resistances.",
"     </li>",
"     <li>",
"      Shunting is accentuated during the early phase of contraction since the left ventricle is activated before the right ventricle and the left ventricular pressure rises faster than the right ventricular pressure.",
"     </li>",
"     <li>",
"      During the early stages of diastole, the left ventricle relaxes more quickly than the right ventricle, resulting in a transient pressure gradient favoring shunting from the right to left ventricle. When PVR is not significantly elevated, blood that is shunted from the right to left ventricle during early diastole flows back into the right ventricle during mid to late diastole as left ventricular diastolic pressure rises. As a result, there is no net ejection of unoxygenated blood into the aorta. However, marked elevation of PVR results in significant right-to-left shunting, with ejection of unoxygenated blood out the aorta and hypoxemia.",
"     </li>",
"     <li>",
"      Additional shunting may occur during mid to late diastole due to the slightly higher left ventricular diastolic pressures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Arterial level shunts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Connections between the aorta and the pulmonary artery include PDA, aorticopulmonary window, aortopulmonary collaterals, and surgically placed aortopulmonary shunts. Similar to a shunt at the ventricular level, the size of a left-to-right shunt at the arterial level depends upon the size of the communication and the relative resistances of the systemic and pulmonary vascular beds. However, in contrast to atrial level shunts, which occur primarily during ventricular diastole, and ventricular level shunts, which occur primarily during ventricular systole, arterial level shunts typically occur throughout the cardiac cycle. This is because the capacitance of the large arteries maintains a pressure during diastole that is greater than the simultaneous pressure in the pulmonary arteries.",
"   </p>",
"   <p>",
"    Large arterial level communications with significant left-to-right shunting may result in widening of the pulse pressure due to runoff of arterial pressure into the pulmonary arteries. In these cases, systemic blood flow is reduced and diastolic and mean blood pressures are lowered. In addition to engaging reflex mechanisms to preserve organ perfusion as noted above with VSDs, this reduction may disproportionately reduce blood flow to the coronary arteries, which are perfused mainly during ventricular diastole.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     OTHER INFLUENCES ON SHUNTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extent or direction of shunting is influenced by the presence of other cardiac lesions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the development of increased pulmonary vascular resistance (PVR) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4344/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Other cardiac lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, lesions that increase impedance to left ventricular filling or ejection downstream from the anatomic level of a communication favor an increase in intracardiac left-to-right shunting. These include mitral stenosis, left ventricular hypertrophy, stenoses of the aortic valve, and increases in systemic vascular resistance (SVR). SVR may be increased by drugs, disease, or obstruction of a vascular bed (eg, ligation of the umbilical artery at birth).",
"   </p>",
"   <p>",
"    In contrast, lesions that increase the impedance to right ventricular filling and ejection favor a decrease in left-to-right shunting, and may even result in right-to-left shunting. Such conditions include right ventricular hypertrophy, stenoses of the right ventricular outflow tract and pulmonary arteries, a surgically placed pulmonary artery band, and disorders that result in increased PVR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Increased PVR",
"    </span>",
"    &nbsp;&mdash;&nbsp;PVR may increase in response to excessive pulmonary blood flow, particularly in the face of the high pulmonary arterial and venous pressures often associated with large ventricular and arterial level shunts. Although reflex pulmonary vasoconstriction occurs in response to the high pressures, this protective mechanism is typically superseded over time by pathologic vascular changes. These changes are irreversible and include fibrous and muscular proliferation in the pulmonary microvasculature and gradual obliteration of the pulmonary vascular bed. They are an expected consequence of long-standing, unrepaired left-to-right shunting in adolescents and young adults. The resultant reversal of the shunt to right-to-left causes cyanosis, and is known as Eisenmenger's syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7304?source=see_link&amp;anchor=H7#H7\">",
"     \"Pathogenesis of pulmonary hypertension\", section on 'Congenital heart disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H852076582\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conditions with left-to-right shunting are due to an abnormal connection between the systemic and pulmonary circulations that leads to excess blood flow from the systemic (&ldquo;left-sided&rdquo;) circulation to the pulmonary (&ldquo;right-sided&rdquo;) circulation. This results in recirculation of some already oxygenated pulmonary venous blood through the pulmonary vasculature. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Pathophysiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac defects with left-to-right shunting include those with intracardiac connections, such as atrial and ventricular septal defects, and vascular connections such as patent ductus arteriosus (PDA) and arteriovenous fistulae. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The physiologic effects and clinical manifestations of left-to-right shunts depend on the shunt size, which is a measure of the excess volume of pulmonary blood flow. Factors that affect this include the location of the anatomic communication, its size, the age of the patient, and the relative resistances to blood flow on either side of the communication. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Shunt size'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Left-to-right shunting can occur due to communications at the atrial, ventricular, and arterial level. This is usually due to a difference in the resistances of each circuit with blood preferentially shunting from a higher to lower resistance circulation. Shunting at each level results in specific pathophysiologic and clinical effects. The different effects result from differences in the downstream resistance to flow on either side of the communication as well as instantaneous differences in the pressures measured in the chambers on either side of the communication during systole and diastole. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Causes of shunting'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The physiologic effects of left-to-right shunt include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Abnormal lung mechanics, such as decreased tidal volume and lung compliance, and increased expiratory airway resistance. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pulmonary effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Activation of the sympathetic nervous system and the renin-angiotensin system. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Neurohumoral activation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Elevated metabolic expenditures with increased respiratory effort and myocardial work that results in poor growth because of decreased nutritional intake (poor intake due to fatigue) and increased catabolism. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Metabolic effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sustained elevation of pulmonary artery pressure, which sometimes reaches the level of systemic pressure. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Pulmonary hypertension'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical presentations of left-to-right shunt vary from patients who are asymptomatic to those who present in heart failure. The variation is dependent on the size of the shunt and its physiologic effects. Typical clinical findings in symptomatic patients include tachypnea, tachycardia and diaphoresis, poor weight gain, and in some patients, hepatomegaly. Patients with left-to-right shunting also are at-risk for viral pulmonary infections, especially respiratory syncytial virus. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because pulmonary vascular resistance (PVR) is elevated at birth, little left-to-right shunting occurs immediately after delivery in term newborns, even those with large communications due to ventricular septal defects (VSDs) or PDA. Shunting typically increases as PVR declines during the first postnatal weeks. Clinical manifestations usually develop as shunting increases. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Fetal and transitional circulation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Time of presentation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Other influences on shunting include the presence of other cardiac lesions that may either favor or impede shunting, and increased PVR. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Other influences on shunting'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4344/abstract/1\">",
"      Iwamoto HS, Teitel D, Rudolph AM. Effects of birth-related events on blood flow distribution. Pediatr Res 1987; 22:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4344/abstract/2\">",
"      Teitel DF, Iwamoto HS, Rudolph AM. Changes in the pulmonary circulation during birth-related events. Pediatr Res 1990; 27:372.",
"     </a>",
"    </li>",
"    <li>",
"     Talner NS. The physiology of congenital heart disease. In: The Science and Practice of Pediatric Cardiology, 2nd ed, Garson A, Bricker TJ, Fisher DJ, Neish SR (Eds), Williams and Wilkins, Baltimore 1998. p.1107.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4344/abstract/4\">",
"      Yau KI, Fang LJ, Wu MH. Lung mechanics in infants with left-to-right shunt congenital heart disease. Pediatr Pulmonol 1996; 21:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4344/abstract/5\">",
"      Vincent RN, Lang P, Elixson EM, et al. Measurement of extravascular lung water in infants and children after cardiac surgery. Am J Cardiol 1984; 54:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4344/abstract/6\">",
"      Baraldi E, Filippone M, Milanesi O, et al. Respiratory mechanics in infants and young children before and after repair of left-to-right shunts. Pediatr Res 1993; 34:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4344/abstract/7\">",
"      Wu JR, Chang HR, Huang TY, et al. Reduction in lymphocyte beta-adrenergic receptor density in infants and children with heart failure secondary to congenital heart disease. Am J Cardiol 1996; 77:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4344/abstract/8\">",
"      Buchhorn R, Hammersen A, Bartmus D, B&uuml;rsch J. The pathogenesis of heart failure in infants with congenital heart disease. Cardiol Young 2001; 11:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4344/abstract/9\">",
"      Koch A, Zink S, Singer H. B-type natriuretic peptide in paediatric patients with congenital heart disease. Eur Heart J 2006; 27:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4344/abstract/10\">",
"      Davlouros PA, Karatza AA, Xanthopoulou I, et al. Diagnostic role of plasma BNP levels in neonates with signs of congenital heart disease. Int J Cardiol 2011; 147:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4344/abstract/11\">",
"      Cameron JW, Rosenthal A, Olson AD. Malnutrition in hospitalized children with congenital heart disease. Arch Pediatr Adolesc Med 1995; 149:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4344/abstract/12\">",
"      Puhakka K, R&auml;s&auml;nen J, Leijala M, Peltola K. Metabolic effects of corrective surgery in infants and children with congenital heart defects. Br J Anaesth 1993; 70:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4344/abstract/13\">",
"      Salzer HR, Haschke F, Wimmer M, et al. Growth and nutritional intake of infants with congenital heart disease. Pediatr Cardiol 1989; 10:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4344/abstract/14\">",
"      Haworth SG. Pulmonary hypertension in childhood. Eur Respir J 1993; 6:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4344/abstract/15\">",
"      Vincent JA, Ross RD, Kassab J, et al. Relation of elevated plasma endothelin in congenital heart disease to increased pulmonary blood flow. Am J Cardiol 1993; 71:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4344/abstract/16\">",
"      Celermajer DS, Cullen S, Deanfield JE. Impairment of endothelium-dependent pulmonary artery relaxation in children with congenital heart disease and abnormal pulmonary hemodynamics. Circulation 1993; 87:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4344/abstract/17\">",
"      Dzimiri N, Galal O, Moorji A, et al. Regulation of sympathetic activity in children with various congenital heart diseases. Pediatr Res 1995; 38:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4344/abstract/18\">",
"      Farrell AG, Schamberger MS, Olson IL, Leitch CA. Large left-to-right shunts and congestive heart failure increase total energy expenditure in infants with ventricular septal defect. Am J Cardiol 2001; 87:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4344/abstract/19\">",
"      Ross RD, Bollinger RO, Pinsky WW. Grading the severity of congestive heart failure in infants. Pediatr Cardiol 1992; 13:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4344/abstract/20\">",
"      Navas L, Wang E, de Carvalho V, Robinson J. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada. J Pediatr 1992; 121:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4344/abstract/21\">",
"      Rhee EK, Evangelista JK, Nigrin DJ, Erickson LC. Impact of anatomic closure on somatic growth among small, asymptomatic children with secundum atrial septal defect. Am J Cardiol 2000; 85:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4344/abstract/22\">",
"      Lister G, Hellenbrand WE, Kleinman CS, Talner NS. Physiologic effects of increasing hemoglobin concentration in left-to-right shunting in infants with ventricular septal defects. N Engl J Med 1982; 306:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4344/abstract/23\">",
"      Schoen SP, Zimmermann T, Kittner T, et al. NT-proBNP correlates with right heart haemodynamic parameters and volumes in patients with atrial septal defects. Eur J Heart Fail 2007; 9:660.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5773 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-259ED97FEC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_15_4344=[""].join("\n");
var outline_f4_15_4344=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H852076582\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FETAL AND TRANSITIONAL CIRCULATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Shunt size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pulmonary effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Neurohumoral activation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Metabolic effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Respiratory effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pulmonary infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Poor growth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Time of presentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CAUSES OF SHUNTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Atrial level shunts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Newborns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Ventricular level shunts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Small VSDs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Moderate VSDs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Large VSDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Associated lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Changes during cardiac cycle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Arterial level shunts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      OTHER INFLUENCES ON SHUNTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Other cardiac lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Increased PVR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H852076582\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5773\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5773|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/43/15032\" title=\"figure 1\">",
"      Fetal circulation 1",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26201?source=related_link\">",
"      Classification and clinical features of isolated atrial septal defects in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/52/35656?source=related_link\">",
"      Clinical manifestations and diagnosis of patent ductus arteriosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/36/3656?source=related_link\">",
"      Partial anomalous pulmonary venous connection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/32/3593?source=related_link\">",
"      Patent foramen ovale",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7304?source=related_link\">",
"      Pathogenesis of pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/19/8506?source=related_link\">",
"      Pathophysiology and clinical features of isolated ventricular septal defects in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13752?source=related_link\">",
"      Pathophysiology, clinical features, and diagnosis of tetralogy of Fallot",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/50/15145?source=related_link\">",
"      Pathophysiology, clinical manifestations, and diagnosis of patent ductus arteriosus in premature infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/19/8502?source=related_link\">",
"      Physiologic transition from intrauterine to extrauterine life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7050?source=related_link\">",
"      Respiratory syncytial virus infection: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/51/10040?source=related_link\">",
"      Total anomalous pulmonary venous connection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/52/14154?source=related_link\">",
"      Ventricular septal defect in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_15_4345="Evaluation of adults with cutaneous lesions of vasculitis";
var content_f4_15_4345=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of adults with cutaneous lesions of vasculitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/15/4345/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/15/4345/contributors\">",
"     Nicole Fett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/15/4345/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/15/4345/contributors\">",
"     Jeffrey Callen, MD, FACP, FAAD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/15/4345/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/15/4345/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/15/4345/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 23, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H16171969\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous vasculitis can occur as a consequence of multiple disorders and is characterized by a wide variety of clinical findings. Because other diseases may present with similar clinical features, histopathologic examination is essential for confirming the diagnosis.",
"   </p>",
"   <p>",
"    Patients with vasculitis are at risk for vasculitis involving other organs. In addition, the cause of cutaneous vasculitis is not always immediately clear. The performance of a thorough patient history and physical examination will guide the selection of the appropriate laboratory and radiologic studies for patient evaluation.",
"   </p>",
"   <p>",
"    The clinical, histopathologic, and laboratory assessment of adults with cutaneous lesions suspicious for vasculitis will be reviewed here. The assessment of childhood vasculitis, the assessment of patients with retiform purpura, and detailed information on specific types of cutaneous vasculitis are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33383?source=see_link\">",
"     \"Approach to evaluating childhood vasculitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39608?source=see_link\">",
"     \"Approach to the patient with retiform (angulated) purpura\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=see_link\">",
"     \"Classification of and approach to the vasculitides in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/41/10904?source=see_link\">",
"     \"Management of adults with idiopathic cutaneous small vessel vasculitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1117785\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous vasculitis results from inflammation of the small or medium-sized blood vessels in the skin. Small blood vessels are capillaries, post-capillary venules, and non-muscular arterioles in the superficial and mid-dermis (&lt;50 &micro;m). Medium-sized vessels consist of 50 to 150 &micro;m vessels with muscular walls in the deep dermis and subcutis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4345/abstract/1-5\">",
"     1-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cutaneous vasculitis occurs in a wide variety of clinical settings (",
"    <a class=\"graphic graphic_table graphicRef59048 \" href=\"UTD.htm?37/14/38125\">",
"     table 1",
"    </a>",
"    ). Examples of vasculitic disorders (vasculitides) that can present with cutaneous lesions include [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4345/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Secondary vasculitis",
"      </strong>",
"      (vasculitis related to bacterial or viral infections, medications, malignancy, or connective tissue diseases and other inflammatory disorders) &ndash; small vessels or small and medium vessels (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30614?source=see_link\">",
"       \"Hypersensitivity vasculitis in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <strong>",
"       Henoch-Sch&ouml;nlein purpura (IgA vasculitis) &ndash;",
"      </strong>",
"      small vessels (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <strong>",
"       Urticarial vasculitis",
"      </strong>",
"      &ndash; small vessels (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/60/32714?source=see_link\">",
"       \"Urticarial vasculitis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <strong>",
"       Cryoglobulinemic vasculitis",
"      </strong>",
"      &ndash; small and medium vessels (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22522?source=see_link\">",
"       \"Overview of cryoglobulins and cryoglobulinemia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <strong>",
"       Microscopic polyangiitis",
"      </strong>",
"      &ndash; small and medium vessels (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link\">",
"       \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <strong>",
"       Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)",
"      </strong>",
"      &ndash; small and medium vessels (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27177?source=see_link\">",
"       \"Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <strong>",
"       Granulomatosis with polyangiitis (Wegener&rsquo;s granulomatosis)",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      small and medium vessels (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link\">",
"       \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <strong>",
"       Polyarteritis nodosa",
"      </strong>",
"      &ndash; medium vessels (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/26/9641?source=see_link\">",
"       \"Clinical manifestations and diagnosis of polyarteritis nodosa\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <strong>",
"       Nodular vasculitis",
"      </strong>",
"      &ndash; medium vessels (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17112?source=see_link&amp;anchor=H4122269#H4122269\">",
"       \"Panniculitis: Recognition and diagnosis\", section on 'Inflammatory disorders'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is estimated that infections, medications, connective tissue diseases, and malignancy account for 23, 20, 12, and 4 percent of cases of cutaneous vasculitis, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4345/abstract/7\">",
"     7",
"    </a>",
"    ]. In contrast, the primary systemic vasculitides (granulomatosis with polyangiitis, polyarteritis nodosa, microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis) are uncommon causes of cutaneous vasculitis. Taken together, they account for only 4 percent of cases. The cause of vasculitis is unidentifiable in 3 to 72 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4345/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/41/10904?source=see_link\">",
"     \"Management of adults with idiopathic cutaneous small vessel vasculitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Erythema elevatum diutinum is a rare form of small vessel vasculitis that presents with red-brown or violaceous papules and nodules over the dorsal hands or extensor surfaces of the extremities (",
"    <a class=\"graphic graphic_picture graphicRef57008 graphicRef67776 \" href=\"UTD.htm?27/54/28518\">",
"     picture 1A-B",
"    </a>",
"    ). Vasculitis is limited to the skin in patients with this disease.",
"   </p>",
"   <p>",
"    Small vessel cutaneous vasculitis may also occur following the use of cocaine adulterated with levamisole, a veterinary anthelminthic that is known to have immunomodulatory properties [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4345/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. Patients often present with tender purpura on the ears and necrotic, retiform purpura on the trunk or extremities (",
"    <a class=\"graphic graphic_picture graphicRef74436 graphicRef77067 graphicRef55590 \" href=\"UTD.htm?11/6/11370\">",
"     picture 2A-C",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H810822\">",
"     'Vasculitis due to levamisole-contaminated cocaine'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606309\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common terms utilized to describe subsets of cutaneous vasculitis include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Small vessel cutaneous vasculitis &ndash;",
"      </strong>",
"      This term encompasses all forms of vasculitis characterized by involvement of small blood vessels in the skin, including neutrophilic, lymphocytic, and granulomatous vasculitides.",
"     </li>",
"     <li>",
"      <strong>",
"       Cutaneous leukocytoclastic vasculitis &ndash;",
"      </strong>",
"      &ldquo;Leukocytoclastic vasculitis&rdquo; is a pathological term that describes the microscopic findings of a neutrophilic small vessel vasculitis (see",
"      <a class=\"local\" href=\"#H16171991\">",
"       'Biopsy'",
"      </a>",
"      below). &ldquo;Cutaneous leukocytoclastic vasculitis&rdquo; is a clinical term that describes this type of vasculitis when it is limited to the skin, such as is common in secondary vasculitides (see",
"      <a class=\"local\" href=\"#H1117785\">",
"       'Etiology'",
"      </a>",
"      above). Alternative terms include",
"      <strong>",
"       cutaneous leukocytoclastic angiitis",
"      </strong>",
"      and",
"      <strong>",
"       cutaneous necrotizing venulitis",
"      </strong>",
"      .",
"     </li>",
"     <li>",
"      <strong>",
"       Hypersensitivity vasculitis &ndash;",
"      </strong>",
"      &ldquo;Hypersensitivity vasculitis&rdquo; refers to cutaneous vasculitis that is secondary to a known or suspected antigen. Use of this term has fallen out of favor with some authors due to the common misclassification of these cases [",
"      <a class=\"abstract\" href=\"UTD.htm?4/15/4345/abstract/7\">",
"       7",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30614?source=see_link\">",
"       \"Hypersensitivity vasculitis in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16171977\">",
"    <span class=\"h1\">",
"     CUTANEOUS FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The morphology of cutaneous lesions of vasculitis is variable and usually correlates with the pathologic process that is occurring in the skin [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4345/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Macular and papular lesions are characteristically nonblanchable due to the presence of extravasated erythrocytes in the dermis, which occurs as a result of damaged vessel walls.",
"   </p>",
"   <p>",
"    Diascopy (the application of pressure to a skin lesion with a glass slide) is a helpful technique for identifying nonblanchable lesions. Blanchable erythematous skin lesions are common in nonvasculitic inflammatory dermatoses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606666\">",
"    <span class=\"h2\">",
"     Common features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common clinical features of cutaneous vasculitis include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Petechiae &ndash;",
"      </strong>",
"      Petechiae are nonblanchable and nonpalpable pinpoint macules (less than a few millimeters in diameter) that result from capillary inflammation and red blood cell extravasation (",
"      <a class=\"graphic graphic_picture graphicRef58626 \" href=\"UTD.htm?22/16/22786\">",
"       picture 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/15/4345/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Palpable purpura &ndash;",
"      </strong>",
"      Palpable purpura are a common manifestation of small vessel vasculitis. Brisk inflammation of venules and arterioles initially manifests as infiltrated erythematous papules and plaques. These progress to raised, nonblanchable (purpuric) lesions as damage to vessel walls increases (",
"      <a class=\"graphic graphic_picture graphicRef79783 graphicRef70300 \" href=\"UTD.htm?41/18/42280\">",
"       picture 4A-B",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/15/4345/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Hemorrhagic bullae &ndash;",
"      </strong>",
"      Small vessel involvement throughout the dermis can result in necrosis of overlying tissue and extravasation of red blood cells (",
"      <a class=\"graphic graphic_picture graphicRef57440 \" href=\"UTD.htm?18/26/18850\">",
"       picture 5",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/15/4345/abstract/2\">",
"       2",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Subcutaneous nodules &ndash;",
"      </strong>",
"      Intense inflammation of medium-sized vessels (vessels with muscular walls in the deep dermis and subcutis) can lead to the formation of nodular lesions (",
"      <a class=\"graphic graphic_picture graphicRef75828 \" href=\"UTD.htm?30/29/31186\">",
"       picture 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Ulceration or digital necrosis &ndash;",
"      </strong>",
"      Ulceration and tissue necrosis occur when vasculitis results in reduced vascular perfusion in the skin (",
"      <a class=\"graphic graphic_picture graphicRef75391 graphicRef58586 \" href=\"UTD.htm?1/36/1606\">",
"       picture 7A-B",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/15/4345/abstract/2\">",
"       2",
"      </a>",
"      ]. Superficial ulcers can occur in patients with small vessel vasculitis; deep ulcers are usually the result of medium vessel disease [",
"      <a class=\"abstract\" href=\"UTD.htm?4/15/4345/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Livedo reticularis and livedo racemosa &ndash;",
"      </strong>",
"      Livedo reticularis presents as a localized or widespread patchy, reticulated, vascular network with a red-blue or violaceous hue (",
"      <a class=\"graphic graphic_picture graphicRef79545 graphicRef61842 \" href=\"UTD.htm?17/33/17941\">",
"       picture 8A-B",
"      </a>",
"      ). It results from compromise of blood flow in medium sized vessels, and can occur in the setting of vasculopathy due to vasospasm, hypercoagulable states, thrombosis, increased blood viscosity, or embolic phenomena, as well as in association with vasculitis. Livedo racemosa presents with a more abrupt and broken vascular pattern than livedo reticularis (",
"      <a class=\"graphic graphic_picture graphicRef64023 \" href=\"UTD.htm?35/42/36512\">",
"       picture 9",
"      </a>",
"      ). It is strongly associated with Sneddon&rsquo;s syndrome, a nonvasculitic disorder characterized by livedoid skin lesions and cerebrovascular accidents, but may also occur in vasculitis and other disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?4/15/4345/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Urticaria &ndash;",
"      </strong>",
"      Unlike nonvasculitic urticaria, lesions of urticarial vasculitis usually persist for more than 24 hours, and frequently are associated with a burning sensation or pain rather than pruritus. Lesions may contain purpuric areas and can resolve with hyperpigmentation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/60/32714?source=see_link\">",
"       \"Urticarial vasculitis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Lesions of cutaneous vasculitis most commonly occur in a symmetrical distribution on the lower legs, dependent areas, or on areas of constrictive clothing due to increased hydrostatic pressure in these sites. The skin lesions are often asymptomatic, but may be associated with pruritus, burning sensations, or pain.",
"   </p>",
"   <p>",
"    The course of the disease is variable; some patients experience a single, limited episode of vasculitis, as is often the case with vasculitis secondary to medications or infection, while other vasculitides are characterized by relapsing or chronic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4345/abstract/14\">",
"     14",
"    </a>",
"    ]. The duration of symptoms ranges from several days to decades [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4345/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606119\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of a petechial or purpuric eruption does not necessarily indicate the presence of vasculitis. Examples of other disorders that may present with these findings include [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4345/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Common causes",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Pigmented purpuric dermatoses",
"      </strong>",
"      (also known as capillaritis; nonblanchable pinpoint macules, patches, or plaques, often on the lower legs) (",
"      <a class=\"graphic graphic_picture graphicRef67127 \" href=\"UTD.htm?25/34/26159\">",
"       picture 10",
"      </a>",
"      ) (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29831?source=see_link&amp;anchor=H20#H20\">",
"       \"Approach to the patient with macular skin lesions\", section on 'Schamberg's disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Macular purpura due to chronic sun exposure",
"      </strong>",
"      (",
"      <a class=\"graphic graphic_picture graphicRef70793 \" href=\"UTD.htm?28/16/28930\">",
"       picture 11",
"      </a>",
"      )",
"      <strong>",
"       , glucocorticoid therapy, trauma, or anticoagulants",
"      </strong>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29831?source=see_link&amp;anchor=H18#H18\">",
"       \"Approach to the patient with macular skin lesions\", section on 'Solar purpura (senile purpura)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Inflammatory disorders on the lower extremities or other dependent sites",
"      </strong>",
"      (eg, stasis dermatitis or maculopapular drug eruptions) (",
"      <a class=\"graphic graphic_picture graphicRef72689 graphicRef80847 \" href=\"UTD.htm?36/51/37686\">",
"       picture 12A-B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <strong>",
"       Arthropod bites",
"      </strong>",
"      (eg, bedbugs) (",
"      <a class=\"graphic graphic_picture graphicRef62345 \" href=\"UTD.htm?34/38/35428\">",
"       picture 13",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Less common causes",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Scurvy",
"      </strong>",
"      (perifollicular hemorrhage) (",
"      <a class=\"graphic graphic_picture graphicRef51219 \" href=\"UTD.htm?26/63/27636\">",
"       picture 14",
"      </a>",
"      ) (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28650?source=see_link&amp;anchor=H63#H63\">",
"       \"Overview of water-soluble vitamins\", section on 'Deficiency'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Platelet deficiencies or dysfunction",
"      </strong>",
"      (petechiae or macular purpura) (",
"      <a class=\"graphic graphic_picture graphicRef76671 \" href=\"UTD.htm?8/17/8468\">",
"       picture 15",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <strong>",
"       Hypercoagulable and thrombotic disorders",
"      </strong>",
"      (noninflammatory retiform purpura) (",
"      <a class=\"graphic graphic_picture graphicRef65890 graphicRef65011 \" href=\"UTD.htm?16/25/16790\">",
"       picture 16A-B",
"      </a>",
"      ) (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39608?source=see_link\">",
"       \"Approach to the patient with retiform (angulated) purpura\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Cholesterol emboli",
"      </strong>",
"      (noninflammatory retiform purpura, digital gangrene, livedo reticularis) (",
"      <a class=\"graphic graphic_picture graphicRef69150 \" href=\"UTD.htm?25/43/26290\">",
"       picture 17",
"      </a>",
"      ) (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31994?source=see_link\">",
"       \"Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Septic emboli",
"      </strong>",
"      (petechiae on the distal extremities, noninflammatory retiform purpura) (",
"      <a class=\"graphic graphic_picture graphicRef57118 \" href=\"UTD.htm?32/29/33235\">",
"       picture 18",
"      </a>",
"      ) (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18249?source=see_link&amp;anchor=H7#H7\">",
"       \"Complications and outcome of infective endocarditis\", section on 'Embolization'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Systemic amyloidosis",
"      </strong>",
"      (periorbital and pinch purpura) (",
"      <a class=\"graphic graphic_picture graphicRef77887 \" href=\"UTD.htm?8/49/8984\">",
"       picture 19",
"      </a>",
"      ) (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35815?source=see_link\">",
"       \"Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Strongyloidiasis",
"      </strong>",
"      (periumbilical purpura) (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11193?source=see_link\">",
"       \"Strongyloidiasis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Purpura fulminans",
"      </strong>",
"      (sharply demarcated purpuric lesions in the setting of disseminated intravascular coagulation or sepsis) (",
"      <a class=\"graphic graphic_picture graphicRef53920 \" href=\"UTD.htm?39/60/40898\">",
"       picture 20",
"      </a>",
"      ) (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=see_link\">",
"       \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37704?source=see_link&amp;anchor=H9#H9\">",
"       \"Clinical manifestations of meningococcal infection\", section on 'Purpura fulminans'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Livedoid vasculopathy",
"      </strong>",
"      (also known as atrophie blanche; presents with punched out ulcers on the lower legs with surrounding livedo reticularis or livedo racemosa) (",
"      <a class=\"graphic graphic_picture graphicRef52262 \" href=\"UTD.htm?26/52/27458\">",
"       picture 21",
"      </a>",
"      ) (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/61/6103?source=see_link\">",
"       \"Livedoid vasculopathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16171984\">",
"    <span class=\"h1\">",
"     CLINICAL ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough history and complete physical examination should be performed on patients who present with cutaneous lesions suggestive of vasculitis. Doing so can offer valuable clues for diagnosis and can assist in determining the appropriate work-up for systemic involvement. Because leukocytoclastic vasculitis secondary to drug and infectious disorders accounts for many cases of cutaneous vasculitis, inquiries regarding new medications and symptoms of infection (particularly upper respiratory infections) are an important part of patient evaluation (see",
"    <a class=\"local\" href=\"#H1117785\">",
"     'Etiology'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4345/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. Knowledge of the timing of the development of vasculitis can be helpful; drug-induced vasculitis most often occurs 7 to 10 days after the introduction of the inciting medication [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4345/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of weight loss, joint pain, sicca symptoms, oral or nasal ulcerations, hair loss, photosensitivity, Raynaud&rsquo;s phenomenon, or cytopenia can suggest the need to evaluate for underlying connective tissue disorders. Hepatitis B and C can induce vasculitis, and symptoms and risk factors for hepatitis should be assessed. Retiform purpura in the context of recent cocaine use suggests the possibility of vasculitis due to use of levamisole-tainted cocaine. (See",
"    <a class=\"local\" href=\"#H1117785\">",
"     'Etiology'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H810822\">",
"     'Vasculitis due to levamisole-contaminated cocaine'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition, patients should be questioned regarding signs or symptoms that could suggest systemic vasculitis. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fatigue, chills, night sweats",
"     </li>",
"     <li>",
"      Myalgias or arthralgias",
"     </li>",
"     <li>",
"      Tea-colored urine or gross hematuria",
"     </li>",
"     <li>",
"      Abdominal pain or melena",
"     </li>",
"     <li>",
"      Chest pain",
"     </li>",
"     <li>",
"      Dyspnea, cough, or hemoptysis",
"     </li>",
"     <li>",
"      New onset or worsening asthma",
"     </li>",
"     <li>",
"      Peripheral neuropathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinicians should also be cognizant of symptoms that suggest the possibility of disorders that mimic vasculitis. (See",
"    <a class=\"local\" href=\"#H606119\">",
"     'Differential diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16171991\">",
"    <span class=\"h1\">",
"     BIOPSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biopsy is an important part of the management of patients with cutaneous lesions that are suspicious for vasculitis. Lesions must be differentiated from those due to nonvasculitic disorders, and the clinical characteristics of skin lesions cannot reliably distinguish between the different types of cutaneous vasculitis. Thus, biopsies should be performed in all patients. Direct immunofluorescence (DIF) studies should also be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606549\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diagnosis of cutaneous vasculitis is confirmed by the identification of criteria that indicate an inflammatory process that results in damage to vessel walls [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4345/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. Small vessels (venules and arterioles) require two out of three of the following criteria for a definitive diagnosis of vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4345/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Angiocentric",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      angioinvasive inflammatory infiltrates",
"     </li>",
"     <li>",
"      Disruption",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      destruction of vessel walls by the inflammatory infiltrate",
"     </li>",
"     <li>",
"      Fibrinoid necrosis (fibrin deposition within the vessel wall or lumen; results from the accumulation and conversion of plasma proteins [",
"      <a class=\"abstract\" href=\"UTD.htm?4/15/4345/abstract/2\">",
"       2",
"      </a>",
"      ])",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Medium-sized vessels (small arteries and veins) in the deep dermis and subcutaneous tissue require both of the following criteria to confirm vasculitis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inflammatory infiltrate infiltrating the muscular vessel wall",
"     </li>",
"     <li>",
"      Fibrinoid necrosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other histopathologic findings that suggest but are not diagnostic for vasculitis include the presence of extravasated erythrocytes, nuclear debris (leukocytoclasia), necrosis of eccrine glands, endothelial cell damage swelling or necrosis, and cutaneous ulceration, infarction, or necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4345/abstract/7\">",
"     7",
"    </a>",
"    ]. Findings that suggest particular forms of vasculitis (eg, granulomas in granulomatosis with polyangiitis [Wegener&rsquo;s granulomatosis] or eosinophilic granulomatosis with polyangiitis [Churg-Strauss syndrome] and interface dermatitis in vasculitis associated with lupus erythematosus or dermatomyositis) represent additional helpful information that can be gleaned from a biopsy.",
"   </p>",
"   <p>",
"    Histopathologic assessment of the biopsy specimen includes the designation of the type of inflammatory infiltrate as neutrophilic (most small and medium vessel vasculitides), lymphocytic, granulomatous, or eosinophilic [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4345/abstract/2\">",
"     2",
"    </a>",
"    ]. These findings can suggest particular forms of vasculitis. For example, granulomatous inflammation occurs in granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis, and lymphocytic vasculitis can be seen in connective tissue disease-associated vasculitis. Other useful diagnostic information can be gleaned from a biopsy; the identification of interface dermatitis can support a diagnosis of vasculitis related to lupus erythematosus or dermatomyositis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1117827\">",
"    <span class=\"h2\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histological characteristics of vasculitic lesions evolve quickly. Lesions that are between 24 and 48 hours old are the most likely to demonstrate diagnostic findings of vasculitis. Biopsies of leukocytoclastic vasculitis taken prior to 24 hours are likely to have some infiltration of neutrophils, but often do not yet exhibit fibrinoid necrosis.",
"   </p>",
"   <p>",
"    Beyond 48 hours, the inflammatory infiltrate in leukocytoclastic vasculitis begins to shift from a neutrophilic infiltrate to lymphocytes and macrophages, and then eventually clears, leaving only evidence of fibrinoid necrosis. Because the nature of the inflammatory infiltrate is of value for diagnosis, we typically ask patients to identify a lesion that has been present for approximately 24 hours for biopsy. (See",
"    <a class=\"local\" href=\"#H606549\">",
"     'Diagnostic criteria'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1117834\">",
"    <span class=\"h2\">",
"     Type of biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cutaneous features seen on clinical exam will dictate what type of biopsy should be performed. We do not perform shave biopsies, as they prevent the evaluation of vessels in the mid and deep dermis (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40264?source=see_link&amp;anchor=H5#H5\">",
"     \"Skin biopsy techniques\", section on 'Biopsy techniques'",
"    </a>",
"    ). The following principles are helpful for guiding the selection of the appropriate biopsy procedure:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cutaneous findings that are suggestive of involvement of the vessels in the superficial to mid dermis (petechiae, palpable purpura, or urticarial papules or plaques) should be evaluated with a punch biopsy that is 4 mm in diameter or larger. This allows for evaluation of vessels throughout the dermis.",
"     </li>",
"     <li>",
"      Cutaneous findings suggestive of involvement of the vessels in the mid-dermis to the subcutaneous tissues (livedo racemosa, subcutaneous nodules, ulcers) require a large punch biopsy (8 to 10 mm) or wedge biopsy that includes the subcutaneous tissue, as the involved vessel may be located there.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45090357\">",
"    <span class=\"h2\">",
"     Location",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biopsies of petechial lesions or palpable purpura can be taken from any site within the lesion. The ideal location of the biopsy differs in patients with livedo racemosa or ulcerations. In livedo",
"    <strong>",
"     racemosa",
"    </strong>",
"    , biopsy should be performed within the pale center of an erythematous ring [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4345/abstract/2\">",
"     2",
"    </a>",
"    ]. This is where the responsible vessel is likely to be located. Biopsies of livedo",
"    <strong>",
"     reticularis",
"    </strong>",
"    demonstrate nonspecific histopathologic findings, and are usually not indicated. (See",
"    <a class=\"local\" href=\"#H606666\">",
"     'Common features'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    When ulceration is present, the biopsy should be taken from the edge of the ulcer, rather than the ulcer itself. A biopsy taken from the base of an ulcer can reveal purely incidental findings of vascular injury that resemble the histopathologic findings of vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4345/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Biopsies of infarcted digits are generally low yield for evaluation for vasculitis, as the infarcted area is simply a manifestation of underlying vessel obstruction. However, when cholesterol emboli or calcific vasculopathy are suspected as an inciting cause of skin lesions that resemble vasculitis, excisional biopsy can be used to evaluate for these diagnoses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31994?source=see_link&amp;anchor=H5889574#H5889574\">",
"     \"Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)\", section on 'Biopsy and pathologic findings'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15017?source=see_link&amp;anchor=H8#H8\">",
"     \"Calciphylaxis\", section on 'Pathology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39608?source=see_link&amp;anchor=H426722#H426722\">",
"     \"Approach to the patient with retiform (angulated) purpura\", section on 'Skin biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16171998\">",
"    <span class=\"h2\">",
"     Direct immunofluorescence studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct immunofluorescence (DIF) is an essential component of the evaluation of cutaneous vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4345/abstract/17\">",
"     17",
"    </a>",
"    ], and should always be performed when available. Direct immunofluorescence utilizes labeled antibodies to identify immunoglobulin and complement deposits within the skin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1117855\">",
"    <span class=\"h3\">",
"     Value",
"    </span>",
"    &nbsp;&mdash;&nbsp;DIF is particularly important for the diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis). Renal involvement is common in this disorder, and distinguishing this diagnosis from the other small vessel vasculitides that can present with identical clinical and histopathologic features is of value. Only the identification of perivascular IgA deposition with DIF confirms the diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4345/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    DIF is also of value for distinguishing immune-complex mediated vasculitides (such as most cases of cutaneous leukocytoclastic vasculitis, Henoch-Sch&ouml;nlein purpura (IgA vasculitis), cryoglobulinemic vasculitis, urticarial vasculitis, and vasculitis secondary to autoimmune connective tissue disease) from pauci-immune vasculitis (granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis, microscopic polyangiitis, and polyarteritis nodosa) (",
"    <a class=\"graphic graphic_table graphicRef59048 \" href=\"UTD.htm?37/14/38125\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4345/abstract/17\">",
"     17",
"    </a>",
"    ]. A negative DIF in the setting of histopathologically confirmed vasculitis should increase suspicion of these pauci-immune primary systemic vasculitides, and an appropriate work up for systemic involvement should be undertaken. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link&amp;anchor=H11701485#H11701485\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27177?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)\", section on 'Evaluation and diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/26/9641?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical manifestations and diagnosis of polyarteritis nodosa\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Finally, DIF can aid in the identification of the underlying etiology of the vasculitis. Predominant deposition of IgM around vessel walls suggests the possibility of vasculitis related to type 2 or type 3 cryoglobulinemia or rheumatoid vasculitis (",
"    <a class=\"graphic graphic_table graphicRef59048 \" href=\"UTD.htm?37/14/38125\">",
"     table 1",
"    </a>",
"    ). Patients with hypocomplementemic urticarial vasculitis may have deposition of IgG, complement, and fibrin on vessel walls as well as along the dermal-epidermal junction [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4345/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22522?source=see_link&amp;anchor=H37#H37\">",
"     \"Overview of cryoglobulins and cryoglobulinemia\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20697?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical manifestations and diagnosis of rheumatoid vasculitis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1117862\">",
"    <span class=\"h3\">",
"     Obtaining the specimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ideally, DIF is performed on a lesion that is",
"    <strong>",
"     less than 24 hours old",
"    </strong>",
"    . The inflammatory reaction stimulated by the deposition of immunoglobulins in vessel walls quickly results in the destruction of both the vessel wall and the immune complexes, resulting in negative immunofluorescence.",
"   </p>",
"   <p>",
"    In contrast to the biopsies for DIF performed for the evaluation of blistering skin diseases, which are taken from perilesional skin, specimens from vasculitic lesions should be taken from within the lesions. Direct immunofluorescence studies cannot be performed on the formalin-fixed tissue obtained for hematoxylin and eosin staining, and a separate tissue specimen should be obtained.",
"   </p>",
"   <p>",
"    Specimens can be placed in Michel&rsquo;s transport medium (a fixative) or normal saline, or can be flash-frozen with liquid nitrogen. Tissue submitted in saline must be processed within 24 hours. Examination of the specimen by a pathologist experienced in DIF microscopy is preferred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16172005\">",
"    <span class=\"h1\">",
"     ADDITIONAL STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because cutaneous vasculitis may be accompanied by systemic vasculitis, the possibility of systemic disease must be considered in all patients with cutaneous lesions (",
"    <a class=\"graphic graphic_table graphicRef59048 \" href=\"UTD.htm?37/14/38125\">",
"     table 1",
"    </a>",
"    ). Cutaneous small vessel vasculitis (aka cutaneous leukocytoclastic vasculitis), which is defined by vasculitis limited to the skin, is a diagnosis of exclusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1117877\">",
"    <span class=\"h2\">",
"     Initial studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following studies are useful for the initial evaluation of the patient with cutaneous lesions consistent with vasculitis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Complete blood count with differential and platelets",
"      </strong>",
"      &ndash; cytopenias may suggest underlying connective tissue disease; leukocytosis can suggest infection or hematologic malignancy; platelet abnormalities may reflect nonvasculitic cause of skin lesions",
"     </li>",
"     <li>",
"      <strong>",
"       Liver function tests &ndash;",
"      </strong>",
"      evaluate for hepatic involvement",
"     </li>",
"     <li>",
"      <strong>",
"       Blood urea nitrogen",
"       <span class=\"nowrap\">",
"        (BUN)/creatinine",
"       </span>",
"       &ndash;",
"      </strong>",
"      evaluates for renal involvement and evaluates renal function",
"     </li>",
"     <li>",
"      <strong>",
"       Urinalysis with microscopy &ndash;",
"      </strong>",
"      identifies hematuria due to renal involvement",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1117885\">",
"    <span class=\"h2\">",
"     Secondary studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the etiology of biopsy-confirmed cutaneous vasculitis is clear (eg, a drug-induced hypersensitivity small vessel cutaneous vasculitis) then further evaluation can be delayed. When the etiology is unclear, we proceed with the following testing:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hepatitis B and C serologies",
"     </li>",
"     <li>",
"      Serum complement levels (CH50, C3, and C4)",
"     </li>",
"     <li>",
"      Antinuclear antibody (ANA) and anti-dsDNA, anti-Ro, anti-La, anti-RNP, and anti-Smith antibodies",
"     </li>",
"     <li>",
"      Rheumatoid factor",
"     </li>",
"     <li>",
"      Serum cryoglobulins",
"     </li>",
"     <li>",
"      Antineutrophil cytoplasmic antibodies (ANCA)",
"     </li>",
"     <li>",
"      Serum and urine protein electrophoresis and immunofixation",
"     </li>",
"     <li>",
"      Human immunodeficiency virus (HIV) antibody",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Positive ANCAs are helpful in the correct clinical context, but do not confirm or eliminate a diagnosis of an ANCA-associated vasculitis. P-ANCA is found in around 60 to 80 percent of patients with microscopic polyangiitis and approximately 50 percent of patients with eosinophilic granulomatosis with polyangiitis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4345/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. C-ANCA is positive in 90 percent of patients with granulomatosis with polyangiitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=see_link\">",
"     \"Clinical spectrum of antineutrophil cytoplasmic antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional laboratory tests are appropriate based upon patient assessment and suspicion for specific underlying disorders. As mentioned above, the cause of vasculitis is unidentifiable in some patients. (See",
"    <a class=\"local\" href=\"#H1117785\">",
"     'Etiology'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/41/10904?source=see_link\">",
"     \"Management of adults with idiopathic cutaneous small vessel vasculitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H810822\">",
"    <span class=\"h3\">",
"     Vasculitis due to levamisole-contaminated cocaine",
"    </span>",
"    &nbsp;&mdash;&nbsp;ANCAs (p-ANCA or both p-ANCA and c-ANCA), antiphospholipid antibodies, and leukopenia or neutropenia are frequently detected in patients with vasculitis or vasculopathy due to levamisole-contaminated cocaine (see",
"    <a class=\"local\" href=\"#H1117785\">",
"     'Etiology'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4345/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=see_link\">",
"     \"Clinical spectrum of antineutrophil cytoplasmic antibodies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27096?source=see_link&amp;anchor=H5#H5\">",
"     \"Diagnosis of the antiphospholipid syndrome\", section on 'Assays for antiphospholipid antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Urine toxicology testing can confirm cocaine use provided cocaine was utilized by the patient in the preceding two to three days. Testing for levamisole in serum or urine is commercially available, but the short half-life of levamisole (5.6 hours) makes the drug difficult to detect. In one series, levamisole was detected in only 2 out of 16 patients (13 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4345/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27096?source=see_link&amp;anchor=H5#H5\">",
"     \"Diagnosis of the antiphospholipid syndrome\", section on 'Assays for antiphospholipid antibodies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32970?source=see_link&amp;anchor=H30#H30\">",
"     \"Cocaine abuse and dependence in adults\", section on 'Drug testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606645\">",
"    <span class=\"h2\">",
"     Chest x-ray",
"    </span>",
"    &nbsp;&mdash;&nbsp;We order chest x-rays in patients who have pulmonary symptoms. ANCA-associated vasculitis can affect the small and medium vessels of the lung, causing inflammation and hemorrhage. Additionally, hypocomplementemic urticarial vasculitis syndrome, a subset of urticarial vasculitis, may present with hemoptysis, pleural effusion, and severe chronic obstructive pulmonary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4345/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606945\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cutaneous vasculitis occurs as a result of inflammatory processes that target and damage small or medium-sized blood vessels in the skin (",
"      <a class=\"graphic graphic_table graphicRef59048 \" href=\"UTD.htm?37/14/38125\">",
"       table 1",
"      </a>",
"      ). A wide variety of disorders can lead to the development of cutaneous vasculitis. Infections and medications are the most common etiologies of cutaneous small vessel vasculitis. (See",
"      <a class=\"local\" href=\"#H1117785\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cutaneous manifestations of vasculitis include petechiae, palpable purpura, nodules, ulcers, and other findings. Clinical features of vasculitis can resemble multiple disorders and biopsy is necessary to confirm the diagnosis. Histopathologic features of vasculitis include fibrinoid necrosis and an inflammatory infiltrate invading or damaging the vessel wall. (See",
"      <a class=\"local\" href=\"#H16171991\">",
"       'Biopsy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H606549\">",
"       'Diagnostic criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Biopsies of lesions of cutaneous vasculitis should be taken from a lesion that is 24 to 48 hours old. Punch biopsies 4 mm in diameter are sufficient for petechial lesions, palpable purpura, or urticarial lesions. Nodules, ulcers, or livedo racemosa require large punch biopsies (8 to 10 mm) or excisional wedge biopsies. (See",
"      <a class=\"local\" href=\"#H1117827\">",
"       'Timing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1117834\">",
"       'Type of biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Biopsies from most lesions of cutaneous vasculitis should be taken from within the lesion. In contrast, biopsies of livedo racemosa should be taken from within the center of an erythematous ring. Biopsies of ulcerated areas should be taken from the edge of the lesion. (See",
"      <a class=\"local\" href=\"#H45090357\">",
"       'Location'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Direct immunofluorescence (DIF) offers valuable clues for diagnosis, and a biopsy for DIF taken from lesional skin should be performed in patients with vasculitic skin lesions. (See",
"      <a class=\"local\" href=\"#H1117855\">",
"       'Value'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Biopsy specimens for DIF should",
"      <strong>",
"       not",
"      </strong>",
"      be placed in formalin. Michel&rsquo;s medium is typically used to preserve the tissue for future processing. Specimens may also be placed in saline or flash-frozen with liquid nitrogen. Specimens placed in saline must be processed within 24 hours. (See",
"      <a class=\"local\" href=\"#H1117862\">",
"       'Obtaining the specimen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Appropriate initial laboratory studies for patients with cutaneous vasculitis include a complete blood count (CBC) with differential and platelets, liver function tests, blood urea nitrogen and creatinine, and urinalysis with microscopy. Additional tests are performed if the cause of vasculitis is unclear or if systemic involvement is suspected. We perform chest x-rays in patients with pulmonary symptoms. (See",
"      <a class=\"local\" href=\"#H16172005\">",
"       'Additional studies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4345/abstract/1\">",
"      Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4345/abstract/2\">",
"      Carlson JA. The histological assessment of cutaneous vasculitis. Histopathology 2010; 56:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4345/abstract/3\">",
"      Gonzalez-Gay MA, Garcia-Porrua C, Pujol RM. Clinical approach to cutaneous vasculitis. Curr Opin Rheumatol 2005; 17:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4345/abstract/4\">",
"      Jennette JC, Falk RJ. The role of pathology in the diagnosis of systemic vasculitis. Clin Exp Rheumatol 2007; 25:S52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4345/abstract/5\">",
"      Nagai Y, Hasegawa M, Igarashi N, et al. Cutaneous manifestations and histological features of microscopic polyangiitis. Eur J Dermatol 2009; 19:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4345/abstract/6\">",
"      Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4345/abstract/7\">",
"      Carlson JA, Ng BT, Chen KR. Cutaneous vasculitis update: diagnostic criteria, classification, epidemiology, etiology, pathogenesis, evaluation and prognosis. Am J Dermatopathol 2005; 27:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4345/abstract/8\">",
"      Gross RL, Brucker J, Bahce-Altuntas A, et al. A novel cutaneous vasculitis syndrome induced by levamisole-contaminated cocaine. Clin Rheumatol 2011; 30:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4345/abstract/9\">",
"      Chung C, Tumeh PC, Birnbaum R, et al. Characteristic purpura of the ears, vasculitis, and neutropenia--a potential public health epidemic associated with levamisole-adulterated cocaine. J Am Acad Dermatol 2011; 65:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4345/abstract/10\">",
"      Ullrich K, Koval R, Koval E, et al. Five consecutive cases of a cutaneous vasculopathy in users of levamisole-adulterated cocaine. J Clin Rheumatol 2011; 17:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4345/abstract/11\">",
"      McGrath MM, Isakova T, Rennke HG, et al. Contaminated cocaine and antineutrophil cytoplasmic antibody-associated disease. Clin J Am Soc Nephrol 2011; 6:2799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4345/abstract/12\">",
"      Xu LY, Esparza EM, Anadkat MJ, et al. Cutaneous manifestations of vasculitis. Semin Arthritis Rheum 2009; 38:348.",
"     </a>",
"    </li>",
"    <li>",
"     Dhadly M, Dean SM, Eberhardt RT. Cutaneous changes in peripheral vascular arterial disease. In: Fitzpatrick's Dermatology in General Medicine, 7th ed, Wolff K, Goldsmith LA, Katz SI.  (Eds), McGraw-Hill, 2008. Vol 2, p.1667.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4345/abstract/14\">",
"      Chen KR, Carlson JA. Clinical approach to cutaneous vasculitis. Am J Clin Dermatol 2008; 9:71.",
"     </a>",
"    </li>",
"    <li>",
"     Chung L, Kea B, Fiorentino DF. Cutaneous vasculitis. In: Dermatology, 2nd ed., Bolognia JL, Jorizzo, JL, et al.  (Eds), Elsevier Limited, Spain 2008. Vol 1, p.347.",
"    </li>",
"    <li>",
"     Piette W. Purpura: mechanisms and differential diagnosis. In: Dermatology, 2nd ed, Bolognia JL, Jorizzo JL, Rapini RP, et al.  (Eds), Elsevier Limited, Spain 2008. Vol 1, p.321.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4345/abstract/17\">",
"      Minz RW, Chhabra S, Singh S, et al. Direct immunofluorescence of skin biopsy: perspective of an immunopathologist. Indian J Dermatol Venereol Leprol 2010; 76:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4345/abstract/18\">",
"      Hung SP, Yang YH, Lin YT, et al. Clinical manifestations and outcomes of Henoch-Sch&ouml;nlein purpura: comparison between adults and children. Pediatr Neonatol 2009; 50:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4345/abstract/19\">",
"      Savige J, Pollock W, Trevisin M. What do antineutrophil cytoplasmic antibodies (ANCA) tell us? Best Pract Res Clin Rheumatol 2005; 19:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4345/abstract/20\">",
"      Grau RG. Churg-Strauss syndrome: 2005-2008 update. Curr Rheumatol Rep 2008; 10:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4345/abstract/21\">",
"      Grotz W, Baba HA, Becker JU, Baumg&auml;rtel MW. Hypocomplementemic urticarial vasculitis syndrome: an interdisciplinary challenge. Dtsch Arztebl Int 2009; 106:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4345/abstract/22\">",
"      Davis MD, Brewer JD. Urticarial vasculitis and hypocomplementemic urticarial vasculitis syndrome. Immunol Allergy Clin North Am 2004; 24:183.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13769 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-B3B70EFBF6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_15_4345=[""].join("\n");
var outline_f4_15_4345=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H606945\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16171969\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1117785\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H606309\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16171977\">",
"      CUTANEOUS FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H606666\">",
"      Common features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H606119\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16171984\">",
"      CLINICAL ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16171991\">",
"      BIOPSY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H606549\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1117827\">",
"      Timing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1117834\">",
"      Type of biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45090357\">",
"      Location",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16171998\">",
"      Direct immunofluorescence studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1117855\">",
"      - Value",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1117862\">",
"      - Obtaining the specimen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16172005\">",
"      ADDITIONAL STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1117877\">",
"      Initial studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1117885\">",
"      Secondary studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H810822\">",
"      - Vasculitis due to levamisole-contaminated cocaine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H606645\">",
"      Chest x-ray",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H606945\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/13769\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13769|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/4/14401\" title=\"picture 1A\">",
"      Erythema elevatum diutinum - lower extremities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/21/17745\" title=\"picture 1B\">",
"      Erythema elevatum diutinum - upper extremities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/28/15810\" title=\"picture 2A\">",
"      Cocaine purpura",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/58/25507\" title=\"picture 2B\">",
"      Cocaine purpura on ear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/53/17235\" title=\"picture 2C\">",
"      Cocaine purpura on extremity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/16/22786\" title=\"picture 3\">",
"      Leukocytoclastic vasculitis - lower leg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/39/19057\" title=\"picture 4A\">",
"      Henoch-Schonlein purpura - IgA vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/37/11862\" title=\"picture 4B\">",
"      Leukocytoclastic vasculitits - palpable purpura",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/26/18850\" title=\"picture 5\">",
"      Leukocytoclastic vasculitis - bullous",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/29/31186\" title=\"picture 6\">",
"      Polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/21/36176\" title=\"picture 7A\">",
"      Cutaneous polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/57/38800\" title=\"picture 7B\">",
"      Cryoglobulinemic vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/33/13841\" title=\"picture 8A\">",
"      Livedo reticularis - lower extremities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/30/35311\" title=\"picture 8B\">",
"      Livedo reticularis - lower leg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/42/36512\" title=\"picture 9\">",
"      Livedo racemosa in polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/34/26159\" title=\"picture 10\">",
"      Schambergs disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/16/28930\" title=\"picture 11\">",
"      Multiple solar purpura",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/2/22560\" title=\"picture 12A\">",
"      Stasis dermatitis petechiae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/27/28082\" title=\"picture 12B\">",
"      Drug eruption purpura",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/38/35428\" title=\"picture 13\">",
"      Bedbug bites in a group",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/63/27636\" title=\"picture 14\">",
"      Scurvy - perifollicular hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/17/8468\" title=\"picture 15\">",
"      Immune thrombocytopenia - ITP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/17/24848\" title=\"picture 16A\">",
"      Antiphospholipid antibody syndrome purpura",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/62/31713\" title=\"picture 16B\">",
"      Antiphospholipid antibody syndrome - purpura",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/43/26290\" title=\"picture 17\">",
"      Cholesterol emboli retiform purpura",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/29/33235\" title=\"picture 18\">",
"      Petechiae in subacute bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/49/8984\" title=\"picture 19\">",
"      Systemic AL amyloidosis purpura",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/60/40898\" title=\"picture 20\">",
"      Purpura fulminans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/52/27458\" title=\"picture 21\">",
"      Livedoid vasculopathy - close view",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13769|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/14/38125\" title=\"table 1\">",
"      Cutaneous vasculitis types",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33383?source=related_link\">",
"      Approach to evaluating childhood vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29831?source=related_link\">",
"      Approach to the patient with macular skin lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39608?source=related_link\">",
"      Approach to the patient with retiform (angulated) purpura",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15017?source=related_link\">",
"      Calciphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=related_link\">",
"      Classification of and approach to the vasculitides in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27177?source=related_link\">",
"      Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=related_link\">",
"      Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=related_link\">",
"      Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=related_link\">",
"      Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/26/9641?source=related_link\">",
"      Clinical manifestations and diagnosis of polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20697?source=related_link\">",
"      Clinical manifestations and diagnosis of rheumatoid vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37704?source=related_link\">",
"      Clinical manifestations of meningococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=related_link\">",
"      Clinical spectrum of antineutrophil cytoplasmic antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32970?source=related_link\">",
"      Cocaine abuse and dependence in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18249?source=related_link\">",
"      Complications and outcome of infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27096?source=related_link\">",
"      Diagnosis of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31994?source=related_link\">",
"      Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30614?source=related_link\">",
"      Hypersensitivity vasculitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/61/6103?source=related_link\">",
"      Livedoid vasculopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/41/10904?source=related_link\">",
"      Management of adults with idiopathic cutaneous small vessel vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22522?source=related_link\">",
"      Overview of cryoglobulins and cryoglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28650?source=related_link\">",
"      Overview of water-soluble vitamins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17112?source=related_link\">",
"      Panniculitis: Recognition and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35815?source=related_link\">",
"      Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40264?source=related_link\">",
"      Skin biopsy techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11193?source=related_link\">",
"      Strongyloidiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/60/32714?source=related_link\">",
"      Urticarial vasculitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_15_4346="Hepatic encephalopathy in adults: Treatment";
var content_f4_15_4346=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hepatic encephalopathy in adults: Treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/15/4346/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/15/4346/contributors\">",
"     Peter Ferenci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/15/4346/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/15/4346/contributors\">",
"     Bruce A Runyon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/15/4346/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/15/4346/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/15/4346/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic encephalopathy or portosystemic encephalopathy (PSE) represents a reversible impairment of neuropsychiatric function associated with impaired hepatic function. Despite the frequency of the condition, we still lack a clear understanding of pathogenesis. Nevertheless, decades of experience have suggested that an increase in ammonia concentration is implicated and that there may be a role for inhibitory neurotransmission through gamma-aminobutyric acid (GABA) receptors in the central nervous system (CNS) and changes in central neurotransmitters and circulating amino acids. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14506?source=see_link\">",
"     \"Hepatic encephalopathy: Pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Currently available therapies for hepatic encephalopathy are based upon these hypotheses (",
"    <a class=\"graphic graphic_table graphicRef64629 \" href=\"UTD.htm?18/9/18589\">",
"     table 1",
"    </a>",
"    ). Some treatments are based upon clinical observations, some upon extrapolation of experimental data obtained in animal models of hepatic encephalopathy, and a smaller number upon controlled, randomized clinical trials. There are a number of problems that interfere with the interpretation of data from these studies (",
"    <a class=\"graphic graphic_table graphicRef55134 \" href=\"UTD.htm?2/50/2860\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A common problem is the variety of clinical conditions that are summarized under the term \"hepatic encephalopathy\". The clinical features of hepatic encephalopathy include a wide range of neuropsychiatric symptoms ranging from minor, not readily discernible signs of altered brain function to overt psychiatric",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      neurologic symptoms to deep coma. As a result, the methods to quantify treatment effects and endpoints are highly variable. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/22/34153?source=see_link\">",
"       \"Clinical manifestations and diagnosis of hepatic encephalopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      It is not known if data regarding treatment in patients with overt hepatic encephalopathy can be extrapolated to minimal hepatic encephalopathy and vice versa. However, many studies included patients both with overt and minimal hepatic encephalopathy.",
"     </li>",
"     <li>",
"      Another important variable is the treatment of control groups. Very few studies use a placebo; in most cases, the new drug was compared to \"standard treatment\" (which by itself may be highly effective) or to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33316?source=see_link\">",
"       lactulose",
"      </a>",
"      (the efficacy of which has only been tested in a prospective placebo-controlled trial recently [",
"      <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/1\">",
"       1",
"      </a>",
"      ]) as \"gold standard\".",
"     </li>",
"     <li>",
"      The sample size of most published studies was small.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will review the treatment of hepatic encephalopathy in patients with chronic liver disease. The approach to patients with acute liver failure is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38538?source=see_link\">",
"     \"Acute liver failure in adults: Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT OF PRECIPITATING CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to recognize that hepatic encephalopathy, acute and chronic, is reversible and that a precipitating cause rather than worsening of hepatocellular function can be identified in the majority of patients. In one classic study, over 80 percent of 100 cases were attributable to such factors as gastrointestinal bleeding, increased protein intake, hypokalemic alkalosis, infection, and constipation (all of which increase arterial ammonia levels), or to hypoxia and the use of sedatives and tranquilizers (",
"    <a class=\"graphic graphic_table graphicRef50440 \" href=\"UTD.htm?0/34/556\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/2\">",
"     2",
"    </a>",
"    ]. Patients with advanced cirrhosis may be particularly sensitive to benzodiazepines because of an increased concentration of benzodiazepine receptor ligands in the brain. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Treatments based upon the GABA hypothesis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Treatment of precipitating events is typically associated with a prompt improvement of hepatic encephalopathy. As a result, every attempt should be made to identify such precipitating events while instituting therapy with the specific agents described below (",
"    <a class=\"graphic graphic_table graphicRef50440 \" href=\"UTD.htm?0/34/556\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17167111\">",
"    <span class=\"h1\">",
"     AGITATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients hospitalized with HE may be agitated. Agitation often resolves upon treatment of the HE; however, patients may represent a hazard to themselves and their caregivers until treatment takes effect. Management may include judicious use of restraints, which may be a safer option than pharmacologic treatment since patients with advanced liver disease and HE may be particularly vulnerable to oversedation with medications. Should medications be required,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    is a safer option than benzodiazepines based mainly on clinical experience and some limited data [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TREATMENTS BASED UPON THE AMMONIA HYPOTHESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gastrointestinal tract is the primary source of ammonia, which enters the circulation via the portal vein. Ammonia is produced by enterocytes from glutamine and by colonic bacterial catabolism of nitrogenous sources such as ingested protein and secreted urea. The intact liver clears almost all of the portal vein ammonia, converting it into glutamine and preventing entry into the systemic circulation. Elevations of ammonia are detected in 60 to 80 percent of patients with hepatic encephalopathy, and therapy aimed at reduction of the circulating ammonia level usually results in resolution of the encephalopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14506?source=see_link\">",
"     \"Hepatic encephalopathy: Pathogenesis\"",
"    </a>",
"    .) Treatment is aimed at either reducing or inhibiting intestinal ammonia production or increasing the removal of ammonia (",
"    <a class=\"graphic graphic_table graphicRef64629 \" href=\"UTD.htm?18/9/18589\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Correction of hypokalemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Correction of hypokalemia, if present, is an essential component of therapy since hypokalemia increases renal ammonia production. The often concurrent metabolic alkalosis may contribute by promoting ammonia entry into the brain by promoting the conversion of ammonium (NH4+), a charged particle which cannot cross the blood-brain barrier, into ammonia (NH3), which can [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/6/6245?source=see_link&amp;anchor=H4#H4\">",
"     \"Hypokalemia-induced renal dysfunction\", section on 'Increased ammonia production'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Reduction in ammoniagenic substrates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Removing the source of the ammonia from the gastrointestinal tract can be an important step in certain patients. The modalities used vary with the clinical setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Lactulose and lactitol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Synthetic disaccharides (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    and lactitol) are currently a mainstay of therapy of hepatic encephalopathy, albeit there is limited evidence from well-designed randomized, controlled trials to demonstrate their efficacy. A systematic review found that lactulose or lactitol (which is not available in the US) were more effective than placebo in improving hepatic encephalopathy (RR of no improvement 0.62, 95% CI 0.46 to 0.84) but had no significant benefit on mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/5\">",
"     5",
"    </a>",
"    ]. However, the benefit on encephalopathy no longer reached statistical significance when the analysis was confined to studies with the highest methodologic quality. The authors also found that antibiotics appeared to be relatively more effective. At least two meta-analyses suggested that lactitol was at least as effective as lactulose, was more palatable, and may have fewer side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. In patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/62/14306?source=see_link\">",
"     lactase",
"    </a>",
"    deficiency, the nonmetabolized lactose has most of the same effects as the synthetic disaccharides in the colon and is much cheaper [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most of the controlled trials included patients with overt hepatic encephalopathy. However, at least one controlled trial published (61 patients) suggested a benefit in patients with minimal hepatic encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/10\">",
"     10",
"    </a>",
"    ]. Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    was associated with improvement in health-related quality of life and cognitive function. These results are striking because the benefit of treating patients with minimal hepatic encephalopathy had not been previously demonstrated, but whether treatment should be routine in such patients is unclear. These findings need to be confirmed in a large, placebo controlled trial.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33316?source=see_link\">",
"     Lactulose",
"    </a>",
"    may also help prevent recurrent hepatic encephalopathy. In a placebo-controlled trial involving 140 patients who recovered from hepatic encephalopathy, patients randomized to lactulose (30 to 60 mL in two to three divided doses so that patients passed two to three soft stools per day) had significantly fewer episodes of recurrent overt hepatic encephalopathy (20 versus 47 percent) during 14 months of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/1\">",
"     1",
"    </a>",
"    ]. However, there were no significant differences in deaths or rates of readmission for causes other than hepatic encephalopathy.",
"   </p>",
"   <p>",
"    The basis for treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    or lactitol is due to the absence of a specific disaccharidase on the microvillus membrane of enterocytes in the human small bowel, thereby permitting entry into the colon. In the colon, lactulose (beta-galactosidofructose) and lactitol (beta-galactosidosorbitol) are catabolized by the bacterial flora to short chain fatty acids (eg, lactic acid and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"     acetic acid",
"    </a>",
"    ) which lower the colonic pH about 5.0. The reduction in pH favors the formation of the nonabsorbable NH4+ from NH3, trapping NH4+ in the colon and effectively reducing plasma ammonia concentrations.",
"   </p>",
"   <p>",
"    Other effects that may contribute to the clinical effectiveness of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    and lactitol include [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased incorporation of ammonia by bacteria for synthesis of nitrogenous compounds",
"     </li>",
"     <li>",
"      Modification of colonic flora, resulting in displacement of urease-containing bacteria with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32004?source=see_link\">",
"       Lactobacillus",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/12\">",
"       12",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Cathartic effects of a hyperosmolar load in the colon which improves the slow gastrointestinal transit in patients with subclinical hepatic encephalopathy",
"     </li>",
"     <li>",
"      Increased fecal nitrogen excretion of up to fourfold due to the increase in stool volume [",
"      <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/13\">",
"       13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Reduced formation of potentially toxic short-chain fatty acids (eg, propionate, butyrate, valerate) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/14\">",
"       14",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    (45 to 90",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    should be titrated to achieve two to three soft stools per day with a pH below 6. Approximately 70 to 80 percent of patients with hepatic encephalopathy improve on lactulose treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/11,15\">",
"     11,15",
"    </a>",
"    ]. Treatment is usually well tolerated, and the principal toxicity is abdominal cramping, diarrhea, and flatulence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Enemas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cleansing of the colon is a rapid and effective method to remove ammoniagenic substrates. It can be achieved either by cathartics or by enemas. A randomized trial involving 20 patients suggested that 1 to 3 L of 20 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    or lactitol solution enemas were more effective than tap water enemas [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/16\">",
"     16",
"    </a>",
"    ]. A possible explanation is that colonic acidification rather than bowel cleansing was the effective therapeutic mechanism.",
"   </p>",
"   <p>",
"    As part of the study, the investigators also randomized a total of 33 patients to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    or lactitol solutions and noted \"a favorable response\" in 78 and 86 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/16\">",
"     16",
"    </a>",
"    ]. The efficacy of oral versus enema administration of lactulose or lactitol is unclear. Its convenience suggests oral administration is the preferred route of administration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Dietary protein reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no good clinical evidence supporting protein restriction in patients with acute hepatic encephalopathy. A randomized trial found no difference between moderate (0.8",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day) and more aggressive protein restriction [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/17\">",
"     17",
"    </a>",
"    ]. A retrospective analysis of prospectively collected data demonstrated that \"higher protein intake was associated with improved hepatic encephalopathy\" in patients with alcoholic hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with grade III to IV hepatic encephalopathy usually do not receive oral nutrition. As soon as they improve, a general diet can be given.",
"   </p>",
"   <p>",
"    A randomized cross-over trial in eight patients suggested that vegetable proteins were superior to proteins derived from fish, milk, or meat with regard to nitrogen balance [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/19\">",
"     19",
"    </a>",
"    ]. As a general rule, only patients who have had a TIPS or surgical portosystemic shunt have hepatic encephalopathy severe enough to warrant use of vegetable protein or protein restriction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Inhibition of intestinal ammonia production and absorption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lowering of blood ammonia levels can be effectively achieved by reducing ammonia production and absorption with antibiotics, synthetic disaccharides (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    ), or the administration of a non-urease-producing bacterium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Oral antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/57/14229?source=see_link\">",
"     Neomycin",
"    </a>",
"    has been used for many years to treat hepatic encephalopathy, but studies have reached variable conclusions regarding its efficacy. A 1977 study found neomycin to be as effective as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    in 33 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/15\">",
"     15",
"    </a>",
"    ], and a subsequent randomized trial that compared neomycin with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37140?source=see_link\">",
"     rifaximin",
"    </a>",
"    in 49 patients with cirrhosis found that both treatments were similarly effective at reducing the neuropsychiatric signs of hepatic encephalopathy and blood ammonia levels [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/20\">",
"     20",
"    </a>",
"    ]. On the other hand, a randomized trial of 39 patients comparing neomycin at a dose of 6 g per day with placebo reported no difference in outcomes between the two treatment groups [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/21\">",
"     21",
"    </a>",
"    ]. In addition, neomycin is associated with ototoxicity and nephrotoxicity, limiting long-term use.",
"   </p>",
"   <p>",
"    Other antibiotics, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    , oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37140?source=see_link\">",
"     rifaximin",
"    </a>",
"    , have been found effective in limited clinical trials and are not associated with the same toxicities as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/57/14229?source=see_link\">",
"     neomycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. However, metronidazole and oral vancomycin are not used commonly. A meta-analysis of five controlled trials of rifaximin found that it had similar efficacy as nonabsorbable disaccharides for acute and chronic hepatic encephalopathy, but was perhaps somewhat better tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/25\">",
"     25",
"    </a>",
"    ]. A randomized trial published after the meta-analysis found that during six months of follow-up, rifaximin was more effective than a placebo in preventing recurrent episodes of hepatic encephalopathy in patients with cirrhosis who had a documented history of recurrent hepatic encephalopathy and were in remission at the start of the trial [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/26\">",
"     26",
"    </a>",
"    ]. Another trial found that rifaximin was associated with improved health-related quality of life compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/27\">",
"     27",
"    </a>",
"    ]. Other placebo-controlled trials found that rifaximin improved quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/28\">",
"     28",
"    </a>",
"    ] and performance on a simulated driving test in patients with minimal hepatic encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/29\">",
"     29",
"    </a>",
"    ]. Rifaximin has received approval from the United States Food and Drug Administration for reducing the risk of overt hepatic encephalopathy recurrence.",
"   </p>",
"   <p>",
"    Thus, antibiotics may be an acceptable choice, but they can all cause alterations in gut flora, and some are substantially more costly than nonabsorbed disaccharides. As a result, they may be best suited for patients who cannot tolerate or are resistant to disaccharides.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Modification of colonic flora (probiotics and prebiotics)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alteration of gut flora (either with probiotics or with prebiotics such as fermentable fiber) has been associated with improvement in hepatic encephalopathy in pilot studies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/30-34\">",
"     30-34",
"    </a>",
"    ]. Such therapy appears to lower blood ammonia concentrations possibly by favoring colonization with acid-resistant, non-urease producing bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/30\">",
"     30",
"    </a>",
"    ]. A meta-analysis of seven trials with 550 participants found that patients treated with probiotics appeared to have reduced plasma ammonia concentrations compared with patients treated with placebo or no intervention (but not when compared with patients who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    ), but the analysis did not demonstrate benefits with regard to clinically relevant outcomes (eg, mortality, quality of life) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An unblinded randomized trial performed after the meta-analysis examined the use of probiotics for secondary prophylaxis of hepatic encephalopathy. The trial assigned 235 patients who had recovered from hepatic encephalopathy to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    , probiotics, or no therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/36\">",
"     36",
"    </a>",
"    ]. Recurrent hepatic encephalopathy occurred in fewer patients who received lactulose or probiotics compared with no treatment (27 and 34 percent, respectively, versus 57 percent). The difference in recurrence rates between those who received lactulose and those who received probiotics was not statistically significant. In addition, arterial ammonia levels decreased following treatment with lactulose or probiotics but were unchanged in those who received no treatment.",
"   </p>",
"   <p>",
"    Another meta-analysis of seven trials with 393 patients supported the efficacy of probiotics for treatment of HE [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/37\">",
"     37",
"    </a>",
"    ]. However, there is still a need for randomized trials with appropriate blinding of participants and investigators and a clear definition of what type of probiotics were used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16554?source=see_link\">",
"     \"Probiotics for gastrointestinal diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Acarbose",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44197?source=see_link\">",
"     Acarbose",
"    </a>",
"    (an inhibitor of alpha glycosidase that is approved for treatment of diabetes mellitus) inhibits the upper gastrointestinal enzymes (alpha-glucosidases) that convert carbohydrates into monosaccharides. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3078?source=see_link\">",
"     \"Alpha-glucosidase inhibitors and lipase inhibitors for treatment of diabetes mellitus\"",
"    </a>",
"    .) It also promotes the proliferation of intestinal saccharolytic bacterial flora while reducing proteolytic flora that produce mercaptans, benzodiazepine-like substances, and ammonia. Their reduction could improve hepatic encephalopathy. This hypothesis appeared to be confirmed by a randomized, controlled crossover trial involving 107 cirrhotic patients with diabetes mellitus and grade 1 to 2 hepatic encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/38\">",
"     38",
"    </a>",
"    ]. Treatment was associated with a significant reduction in blood ammonia levels and improvement in encephalopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Stimulation of metabolic ammonia metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ammonia is removed by formation of urea in periportal hepatocytes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    by synthesis of glutamine from glutamate in perivenous hepatocytes. In cirrhosis, the activities of carbamyl phosphate synthetase and of glutamine synthetase (the key enzymes for urea and glutamine synthesis) are impaired and the glutaminase flux is increased in a compensatory fashion, resulting in hyperammonemia. As a result, ornithine-aspartate and benzoate have been used to lower plasma ammonia concentrations by enhancing the metabolism of ammonia to glutamine and hippurate, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Ornithine-aspartate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ornithine serves both as an activator of carbamyl phosphate synthetase and ornithine-carbamyl transferase in periportal hepatocytes, and as a substrate for ureagenesis. Ornithine (via alpha-ketoglutarate) and aspartate increase ammonia removal by these cells via stimulation of glutamine synthesis.",
"   </p>",
"   <p>",
"    Several controlled trials have suggested a benefit of ornithine-aspartate in patients with mild hepatic encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/39-42\">",
"     39-42",
"    </a>",
"    ]. As an example, one study of 126 patients with cirrhosis, hyperammonemia, and chronic hepatic encephalopathy were randomly assigned to treatment with ornithine-aspartate (20 g infusion over four hours for seven days) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/40\">",
"     40",
"    </a>",
"    ]. Patients with mildly symptomatic hepatic encephalopathy in the active treatment group had significant improvements in fasting and postprandial blood ammonia concentrations compared with placebo, as well as improvement in clinical measures. There was no effect in patients with subclinical hepatic encephalopathy. A smaller placebo-controlled study also found benefits of oral ornithine-aspartate (18",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    with no adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/41\">",
"     41",
"    </a>",
"    ]. In an open label prospective observational study, treatment of HE with oral L-ornithine-L-aspartate in patients with cirrhosis markedly improved HR-QOL and was well tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, the available data are mixed but suggest that in patients with mild hepatic encephalopathy and cirrhosis, ornithine-aspartate may be somewhat more effective than placebo, but further studies are needed. Ornithine-aspartate has not been compared directly with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    or lactitol in randomized trials and experience in patients with more severe hepatic encephalopathy is limited.",
"   </p>",
"   <p>",
"    By contrast, discordant data have been published in patients with acute liver failure. In aggregate, they suggest that ornithine aspartate is ineffective in such patients. An illustrative study included 201 patients with acute liver failure who were randomly assigned to either placebo or ornithine-aspartate infusions (30 g daily) for three days. Active treatment had no effect on the improvement in encephalopathy grade, consciousness recovery time, survival time, or complications such as seizures and renal failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Sodium benzoate",
"    </span>",
"    &nbsp;&mdash;&nbsp;An entirely different approach to eliminate ammonia is the use of benzoate. Benzoate reacts with glycine to form hippurate. For each mole of benzoate used, one mole of waste nitrogen is excreted into the urine.",
"   </p>",
"   <p>",
"    A prospective, randomized, double-blind study of 74 patients with acute hepatic encephalopathy found that treatment with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/6/32866?source=see_link\">",
"     sodium benzoate",
"    </a>",
"    (5 gm twice daily) resulted in similar improvements in encephalopathy as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/44\">",
"     44",
"    </a>",
"    ]. There was no placebo group. The cost of lactulose was 30 times that of sodium benzoate.",
"   </p>",
"   <p>",
"    While this study is encouraging, we are reluctant to recommend",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/6/32866?source=see_link\">",
"     sodium benzoate",
"    </a>",
"    as first line therapy prior to a trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    until the results are confirmed in a placebo-controlled study, given the much broader experience with lactulose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TREATMENTS BASED UPON THE FALSE NEUROTRANSMITTER HYPOTHESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been suggested that increases in the ratio of plasma aromatic amino acids (AAA) to branched-chain amino acids (BCAA) as a consequence of hepatic insufficiency could contribute to encephalopathy. The altered ratio could then increase brain levels of aromatic amino acid precursors for monoamine neurotransmitters and contribute to altered neuronal excitability. As a result, a number of studies have evaluated the effects of the provision of BCAA, given either intravenously or orally.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     BCAA infusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several randomized, controlled studies have evaluated the use of parenteral nutrition with modified amino acid solutions with a high content of BCAA and a low content of AAA [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. A meta-analysis suggested that mental recovery was consistently more rapid in treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/46\">",
"     46",
"    </a>",
"    ]. Three studies suggested lower mortality in treated patients while two others suggested that treatment increased mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/46\">",
"     46",
"    </a>",
"    ]. The studies included in this meta-analysis differed with respect to the amino acid solutions used, the study protocols, patient selection, and the duration of treatment, and therefore cannot be compared directly with each other. In addition, all studies were of relatively short duration. We do not presently consider infusions of modified amino acid solutions or BCAA as standard treatment of patients with hepatic encephalopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Oral BCAA supplements",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of oral branched chain amino acid supplements (BCAA) is unclear. A systematic review of 11 randomized trials (with a total of 556 patients) found no convincing evidence of a benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/47\">",
"     47",
"    </a>",
"    ]. However, significant improvement in chronic hepatic encephalopathy has been described in some of the trials. As an example, a double-blind trial of 64 patients found that long-term supplementation of oral BCAA to a low protein diet was more likely to improve mental performance at three months than supplementation with casein (80 versus 35 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/48\">",
"     48",
"    </a>",
"    ]. In addition, some patients who did not improve on casein rapidly improved when switched to BCAA. Another report evaluated 37 hospitalized protein-intolerant patients with cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/49\">",
"     49",
"    </a>",
"    ]. The addition of BCAA to the diet enabled the daily protein intake to be increased to up to 80 g without worsening cerebral function; in comparison, many control patients (receiving casein as a protein source) deteriorated after increasing dietary protein intake. No benefit of BCAA supplementation was observed in protein-tolerant patients. A subsequent randomized controlled trial of 116 patients who had an episode of hepatic encephalopathy found no benefit of BCAA on recurrent encephalopathy, although supplementation appeared to improve minimal hepatic encephalopathy and muscle mass [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/50\">",
"     50",
"    </a>",
"    ]. Based upon these results, we feel that dietary BCAA supplementation is indicated only in severely protein-intolerant patients.",
"   </p>",
"   <p>",
"    The data of a Cochrane analysis of 37 studies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/51\">",
"     51",
"    </a>",
"    ] do not justify the routine use of parenteral nutrition, enteral nutrition, or oral nutritional supplements in patients with liver disease (including the use of BCAA for patients with hepatic encephalopathy). The fact that all but one of these trials were at high risk of bias even casts doubt on the few benefits that were demonstrated. Data from well-designed and executed randomized trials that include an untreated control group are needed before any such recommendation can be made.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     TREATMENTS BASED UPON THE GABA HYPOTHESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The GABA-receptor complex appears to be a contributor to neuronal inhibition in hepatic encephalopathy. This complex, in the postsynaptic membrane, is the principal inhibitory network in the central nervous system. It consists of a GABA-binding site, a chloride channel, and barbiturate and benzodiazepine receptor sites. Increases in transmission could be caused by increases in ligands for any of the three receptors. Since there is evidence for an increase in benzodiazepine receptor ligands in patients with hepatic encephalopathy, the effects of benzodiazepine receptor antagonists have been studied [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. GABA-ergic transmission may interact with ammonia in the pathogenesis of hepatic encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14506?source=see_link\">",
"     \"Hepatic encephalopathy: Pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The benzodiazepine receptor antagonist",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/6/41062?source=see_link\">",
"     flumazenil",
"    </a>",
"    has been used for treatment of hepatic encephalopathy in a number of uncontrolled studies and in several controlled trials with limited success [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/55-59\">",
"     55-59",
"    </a>",
"    ]. Response to treatment, when it occurred, was seen within a few minutes after intravenous administration in most patients; however, two-thirds of the patients who responded deteriorated two to four hours later. The controlled trials varied in design and exclusion criteria, and are therefore not directly comparable.",
"   </p>",
"   <p>",
"    The available data were summarized in a systematic review of 12 controlled trials that included a total of 765 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/60\">",
"     60",
"    </a>",
"    ]. The authors concluded that treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/6/41062?source=see_link\">",
"     flumazenil",
"    </a>",
"    was associated with a significant improvement in hepatic encephalopathy compared with placebo at the end of treatment (30 versus 7 percent, absolute improvement of 23 percent (95% CI 18 to 28 percent)). The benefit was short-term, and appeared to be confined to patients who otherwise had a favorable prognosis. No significant benefit on recovery or survival was demonstrated. A second meta-analysis that included six of the controlled trials reached similar estimates of efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These findings suggest that while some patients with hepatic encephalopathy may benefit from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/6/41062?source=see_link\">",
"     flumazenil",
"    </a>",
"    , it cannot be recommended as routine therapy. Flumazenil may be helpful, however, in patients who have received benzodiazepines. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11080?source=see_link\">",
"     \"Benzodiazepine poisoning and withdrawal\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     MISCELLANEOUS TREATMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Zinc and melatonin have been suggested as having potential value in some patients with chronic or recurring hepatic encephalopathy, although little evidence exists to document their effectiveness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Zinc",
"    </span>",
"    &nbsp;&mdash;&nbsp;Zinc deficiency is common in patients with cirrhosis and in those with hepatic encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/62\">",
"     62",
"    </a>",
"    ]. Zinc is contained in vesicles in presynaptic terminals of a class of neurons, many of which are a subclass of the glutamatergic neurons [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/63\">",
"     63",
"    </a>",
"    ]. Stimulated release may modulate ion channel function and neurotransmission [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/64\">",
"     64",
"    </a>",
"    ]. Zinc may also enhance the hepatic conversion of amino acids into urea [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Little information is available on the clinical effects of zinc supplementation in overt hepatic encephalopathy. A patient has been described who exhibited a relationship between zinc deficiency and severe recurrent hepatic encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/66\">",
"     66",
"    </a>",
"    ]. The study included a period in which zinc deficiency was artificially induced by oral histidine. An episode of overt encephalopathy occurred that was identical to earlier episodes and responded to oral zinc. Long-term zinc supplementation significantly improved severe recurrent hepatic encephalopathy which had been refractory to protein restriction,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/57/14229?source=see_link\">",
"     neomycin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    However, this anecdotal report has not been confirmed in larger studies. As an example, short-term zinc supplementation had no clinically significant effect in 15 patients with chronic hepatic encephalopathy studied in a blinded crossover trial [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/67\">",
"     67",
"    </a>",
"    ]. As a result, we do not recommend zinc supplementation for treatment of hepatic encephalopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Melatonin",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the most frequently described, sometimes disabling symptoms of subclinical forms of hepatic encephalopathy are sleep disturbances or, more generally, alterations in the",
"    <span class=\"nowrap\">",
"     sleep/wake",
"    </span>",
"    cycle. Unsatisfactory sleep is also characteristic of patients with cirrhosis who do not have encephalopathy (48 percent of patients in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/68\">",
"     68",
"    </a>",
"    ]).",
"   </p>",
"   <p>",
"    The abnormalities in sleep may be due in part to alterations in the 24-hour rhythm of the hormone melatonin, which is considered to be the output signal of the biological \"clock\". (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13034?source=see_link\">",
"     \"Physiology and clinical use of melatonin\"",
"    </a>",
"    .) In one series of patients with cirrhosis, the onset of the rise in plasma concentrations of melatonin and the melatonin peak during the night were displaced to later hours [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/69\">",
"     69",
"    </a>",
"    ]. Furthermore, plasma melatonin levels in patients with cirrhosis were significantly higher during daylight hours, at a time when melatonin is normally very low or absent.",
"   </p>",
"   <p>",
"    These findings support the hypothesis that an alteration of circadian rhythmicity is responsible for the disruption in the",
"    <span class=\"nowrap\">",
"     sleep/wake",
"    </span>",
"    cycle frequently seen in cirrhosis. Melatonin can influence its own rhythm when administered at defined time points of the day, shifting the curve forward or backward [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/70\">",
"     70",
"    </a>",
"    ]. Some authorities have tried orally administered melatonin in patients with cirrhosis who have an altered",
"    <span class=\"nowrap\">",
"     sleep/wake",
"    </span>",
"    cycles. However, our clinical experience with this drug has not revealed a benefit in patients with cirrhosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13034?source=see_link\">",
"     \"Physiology and clinical use of melatonin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     EXPERIMENTAL TREATMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of experimental approaches are being evaluated in animal models for the treatment of hepatic encephalopathy. Few have received any testing in clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     L-Carnitine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     Carnitine",
"    </a>",
"    is a metabolite in the degradation pathway of the essential amino acid lysine and is synthesized by oxidation of E-amino-trimethyl-lysine. It serves as a carrier for short chain fatty acids across the mitochondrial membrane. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14200?source=see_link&amp;anchor=H2#H2\">",
"     \"Carnitine metabolism in renal disease and dialysis\", section on 'Role of carnitine in intermediary metabolism'",
"    </a>",
"    .) Data in portacaval-shunted rats suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    is protective against ammonia neurotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/71,72\">",
"     71,72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The available clinical data are insufficient to assess the role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    in human disease. In patients with cirrhosis who were subjected to a rectal ammonium overload test, intravenous L-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    improved psychometric tests significantly after 30 minutes, whereas circulating ammonia levels were not influenced [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/73\">",
"     73",
"    </a>",
"    ]. However, the increase in plasma ammonia after rectal ammonia overload was significantly lower in treated patients with evidence of portal hypertension than in patients without these signs.",
"   </p>",
"   <p>",
"    Treatment with acetyl-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    treatment has been tested in a randomized trial of patients with minimal hepatic encephalopathy. The trial included 67 patients who were assigned to receive acetyl-L-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    or placebo. Patients treated with acetyl-L-carnitine had more improvement in energy levels, general functioning, and well-being than those who received placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Glutamatergic antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is good evidence that the glutamatergic neurotransmitter system is involved in the pathogenesis of hepatic encephalopathy. The N-methyl-D-aspartate (NMDA) receptor is one of three known central glutamate receptors. NMDA overactivity has been observed in two different experimental rat models of encephalopathy. The administration of the NMDA receptor antagonist",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/16/24837?source=see_link\">",
"     memantine",
"    </a>",
"    resulted in a significant improvement in clinical grading and less slowing of EEG activity, smaller increases in CSF glutamate concentrations, and lower intracranial pressure and brain water content than in untreated control rats [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Serotonin antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accumulated neurochemical data in different animal models of fulminant hepatic failure and in humans with hepatic encephalopathy suggest that serotoninergic tone is increased in the brain in hepatic encephalopathy. The nonselective serotonin receptor antagonist methysergide had no effect in control rats, but increased motor activity in rats with stage II to III hepatic encephalopathy stage in a dose-dependent manner; in contrast, the 5-HT2 receptor antagonist seganserin had no effect [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Opioid antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma levels of Met-enkephalin and beta-endorphin are elevated in patients and in experimental animals suffering from liver failure. Administration of",
"    <span class=\"nowrap\">",
"     (+/-)-naltrexone,",
"    </span>",
"    but not (+)-naloxone, significantly increased the motor activity of rats with stage III hepatic encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15422219\">",
"    <span class=\"h1\">",
"     PROGNOSIS AFTER RECOVERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with overt hepatic encephalopathy may have persistent and cumulative neurologic deficits despite an apparent normalization of mental status after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. In a study that summarized the results of two cohorts of patients with cirrhosis, for example, overt hepatic encephalopathy was associated with persistent deficits in working memory, response inhibition, and learning when assessed by psychometric testing [",
"    <a class=\"abstract\" href=\"UTD.htm?4/15/4346/abstract/78\">",
"     78",
"    </a>",
"    ]. The number of episodes of overt hepatic encephalopathy correlated with the severity of residual impairment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (See",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/40/7810?source=see_link\">",
"       \"Patient information: Hepatic encephalopathy (The Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Acute therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial management of overt hepatic encephalopathy type C (ie, caused by cirrhosis and portal hypertension",
"    <span class=\"nowrap\">",
"     /or",
"    </span>",
"    systemic shunts) involves two steps:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Identification and correction of precipitating causes",
"     </li>",
"     <li>",
"      Measures to lower the blood ammonia concentration",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Correction of precipitating causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step is the identification and correction of precipitating causes. Careful evaluation should be performed to determine the presence of any of the following (",
"    <a class=\"graphic graphic_table graphicRef50440 \" href=\"UTD.htm?0/34/556\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypovolemia",
"     </li>",
"     <li>",
"      Gastrointestinal bleeding",
"     </li>",
"     <li>",
"      Hypokalemia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      metabolic alkalosis",
"     </li>",
"     <li>",
"      Hypoxia",
"     </li>",
"     <li>",
"      Sedatives or tranquilizers",
"     </li>",
"     <li>",
"      Hypoglycemia",
"     </li>",
"     <li>",
"      Infection (including spontaneous bacterial peritonitis)",
"     </li>",
"     <li>",
"      Vascular occlusion (hepatic vein or portal vein thrombosis)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Approximately 70 to 80 percent of patients with hepatic encephalopathy improve after correction of precipitating factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Lower blood ammonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The second step is initiation of measures to lower the blood ammonia concentrations (whether or not the values are frankly elevated). Correction of hypokalemia is also an essential component of therapy since hypokalemia increases renal ammonia production. We do not recommend dietary protein restriction in patients with acute hepatic encephalopathy.",
"   </p>",
"   <p>",
"    Drug therapy is the mainstay of treatment to lower the blood ammonia concentration. There are no large comparative trials to determine whether disaccharides, ornithine-aspartate, or benzoate are more effective for initial treatment of hepatic encephalopathy. Our approach to drug therapy is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest initiating drug therapy for acute hepatic encephalopathy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33316?source=see_link\">",
"       lactulose",
"      </a>",
"      or lactitol (in countries in which it is available; lactitol is not available in the United States) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). While a well-performed, placebo-controlled study of lactulose therapy has not been performed, there is extensive clinical experience supporting its efficacy. The dose of lactulose (45 to 90",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      should be titrated to achieve two to three soft stools per day with a pH below 6. Lactulose enemas can be given if the patient cannot take lactulose orally. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Lactulose and lactitol'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An acceptable alternative is infusion of ornithine-aspartate (20 g infusion per day given over four hours). The drug is not available in the United States. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Ornithine-aspartate'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For those who have not improved within 48 hours, we suggest second-line therapy with non-absorbed antibiotics (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). As a general rule, antibiotics are added to rather than substituted for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33316?source=see_link\">",
"       lactulose",
"      </a>",
"      . Whether a combination of lactulose with antibiotics provides a benefit for the patient is unknown.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/57/14229?source=see_link\">",
"     Neomycin",
"    </a>",
"    has been used as a second-line therapy in patients who have not responded to disaccharides, but we are concerned about its lack of efficacy in a placebo-controlled trial and its theoretical potential for ototoxicity and nephrotoxicity. Various doses have been used but we generally use 500 mg three times a day or 1 gram twice daily. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Oral antibiotics'",
"    </a>",
"    above.) With regard to the nephrotoxicity, only a few cases have been described and thus the risk (although unknown) is probably very low. In patients with deep hepatic encephalopathy (coma), some authorities prefer to give",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    by enema for several days, reserving neomycin for those who do not respond.",
"   </p>",
"   <p>",
"    An alternative is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37140?source=see_link\">",
"     rifaximin",
"    </a>",
"    (400 mg taken orally three times daily or 550 mg taken orally two times a day).",
"   </p>",
"   <p>",
"    A further alternative is",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/6/32866?source=see_link\">",
"     sodium benzoate",
"    </a>",
"    (5 g twice daily). Sodium benzoate is not available as a pharmaceutical in the United States or the European Union. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Oral antibiotics'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H13\">",
"     'Stimulation of metabolic ammonia metabolism'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Chronic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with recurrent type C encephalopathy (ie, caused by cirrhosis and portal",
"    <span class=\"nowrap\">",
"     hypertension/systemic",
"    </span>",
"    shunts), we suggest continuous administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    &nbsp;(",
"    <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"     Grade 2B",
"    </a>",
"    ). Protein restriction is not needed unless encephalopathy is resistant to lactulose. In patients whose symptoms worsen with protein intake, substitution of proteins from fish, milk, or meat with vegetable proteins may improve nitrogen balance. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Dietary protein reduction'",
"    </a>",
"    above.) Another alternative for patients intolerant to protein is the addition of branched-chain amino acids (BCAA) to a low protein diet. BCAA supplementation is indicated only in severely protein-intolerant patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Minimal hepatic encephalopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with minimal hepatic encephalopathy may benefit from treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    , but the decision to treat should be individualized based upon the results of psychometric testing and the degree to which the encephalopathy has an impact on quality of life.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/1\">",
"      Sharma BC, Sharma P, Agrawal A, Sarin SK. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology 2009; 137:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/2\">",
"      Fessel JN, Conn HO. An analysis of the causes and prevention of hepatic coma. Gastroenterology 1972; 62:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/3\">",
"      Prabhakar S, Bhatia R. Management of agitation and convulsions in hepatic encephalopathy. Indian J Gastroenterol 2003; 22 Suppl 2:S54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/4\">",
"      Gabduzda GJ, Hall PW 3rd. Relation of potassium depletion to renal ammonium metabolism and hepatic coma. Medicine (Baltimore) 1966; 45:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/5\">",
"      Als-Nielsen B, Gluud LL, Gluud C. Nonabsorbable disaccharides for hepatic encephalopathy. Cochrane Database Syst Rev 2004; :CD003044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/6\">",
"      Morgan MY, Hawley KE. Lactitol vs. lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double-blind, randomized trial. Hepatology 1987; 7:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/7\">",
"      Blanc P, Daures JP, Rouillon JM, et al. Lactitol or lactulose in the treatment of chronic hepatic encephalopathy: results of a meta-analysis. Hepatology 1992; 15:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/8\">",
"      Camm&agrave; C, Fiorello F, Tin&egrave; F, et al. Lactitol in treatment of chronic hepatic encephalopathy. A meta-analysis. Dig Dis Sci 1993; 38:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/9\">",
"      Uribe-Esquivel M, Moran S, Poo JL, Mu&ntilde;oz RM. In vitro and in vivo lactose and lactulose effects on colonic fermentation and portal-systemic encephalopathy parameters. Scand J Gastroenterol Suppl 1997; 222:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/10\">",
"      Prasad S, Dhiman RK, Duseja A, et al. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 2007; 45:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/11\">",
"      Ferenci P, Herneth A, Steindl P. Newer approaches to therapy of hepatic encephalopathy. Semin Liver Dis 1996; 16:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/12\">",
"      Riggio O, Varriale M, Testore GP, et al. Effect of lactitol and lactulose administration on the fecal flora in cirrhotic patients. J Clin Gastroenterol 1990; 12:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/13\">",
"      Mortensen PB. The effect of oral-administered lactulose on colonic nitrogen metabolism and excretion. Hepatology 1992; 16:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/14\">",
"      Mortensen PB, Holtug K, Bonn&eacute;n H, Clausen MR. The degradation of amino acids, proteins, and blood to short-chain fatty acids in colon is prevented by lactulose. Gastroenterology 1990; 98:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/15\">",
"      Conn HO, Leevy CM, Vlahcevic ZR, et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology 1977; 72:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/16\">",
"      Uribe M, Campollo O, Vargas F, et al. Acidifying enemas (lactitol and lactose) vs. nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: a double-blind, randomized clinical trial. Hepatology 1987; 7:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/17\">",
"      C&oacute;rdoba J, L&oacute;pez-Hell&iacute;n J, Planas M, et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol 2004; 41:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/18\">",
"      Morgan TR, Moritz TE, Mendenhall CL, Haas R. Protein consumption and hepatic encephalopathy in alcoholic hepatitis. VA Cooperative Study Group #275. J Am Coll Nutr 1995; 14:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/19\">",
"      Bianchi GP, Marchesini G, Fabbri A, et al. Vegetable versus animal protein diet in cirrhotic patients with chronic encephalopathy. A randomized cross-over comparison. J Intern Med 1993; 233:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/20\">",
"      Miglio F, Valpiani D, Rossellini SR, Ferrieri A. Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial. Curr Med Res Opin 1997; 13:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/21\">",
"      Strauss E, Tramote R, Silva EP, et al. Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. Hepatogastroenterology 1992; 39:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/22\">",
"      Tarao K, Ikeda T, Hayashi K, et al. Successful use of vancomycin hydrochloride in the treatment of lactulose resistant chronic hepatic encephalopathy. Gut 1990; 31:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/23\">",
"      Bucci L, Palmieri GC. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin 1993; 13:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/24\">",
"      Williams R, James OF, Warnes TW, Morgan MY. Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study. Eur J Gastroenterol Hepatol 2000; 12:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/25\">",
"      Jiang Q, Jiang XH, Zheng MH, et al. Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis. Eur J Gastroenterol Hepatol 2008; 20:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/26\">",
"      Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010; 362:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/27\">",
"      Sanyal A, Younossi ZM, Bass NM, et al. Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study. Aliment Pharmacol Ther 2011; 34:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/28\">",
"      Sidhu SS, Goyal O, Mishra BP, et al. Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial). Am J Gastroenterol 2011; 106:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/29\">",
"      Bajaj JS, Heuman DM, Wade JB, et al. Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology 2011; 140:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/30\">",
"      Liu Q, Duan ZP, Ha DK, et al. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004; 39:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/31\">",
"      MACBETH WA, KASS EH, MCDERMOTT WV Jr. TREATMENT OF HEPATIC ENCEPHALOPATHY BY ALTERATION OF INTESTINAL FLORA WITH LACTOBACILLUS ACIDOPHILUS. Lancet 1965; 1:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/32\">",
"      Read AE, McCarthy CF, Heaton KW, Laidlaw J. Lactobacillus acidophilus (enpac) in treatment of hepatic encephalopathy. Br Med J 1966; 1:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/33\">",
"      Loguercio C, Abbiati R, Rinaldi M, et al. Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy. J Hepatol 1995; 23:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/34\">",
"      Bajaj JS, Saeian K, Christensen KM, et al. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am J Gastroenterol 2008; 103:1707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/35\">",
"      McGee RG, Bakens A, Wiley K, et al. Probiotics for patients with hepatic encephalopathy. Cochrane Database Syst Rev 2011; :CD008716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/36\">",
"      Agrawal A, Sharma BC, Sharma P, Sarin SK. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy. Am J Gastroenterol 2012; 107:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/37\">",
"      Holte K, Krag A, Gluud LL. Systematic review and meta-analysis of randomized trials on probiotics for hepatic encephalopathy. Hepatol Res 2012; 42:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/38\">",
"      Gentile S, Guarino G, Romano M, et al. A randomized controlled trial of acarbose in hepatic encephalopathy. Clin Gastroenterol Hepatol 2005; 3:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/39\">",
"      Staedt U, Leweling H, Gladisch R, et al. Effects of ornithine aspartate on plasma ammonia and plasma amino acids in patients with cirrhosis. A double-blind, randomized study using a four-fold crossover design. J Hepatol 1993; 19:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/40\">",
"      Kircheis G, Nilius R, Held C, et al. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology 1997; 25:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/41\">",
"      Stauch S, Kircheis G, Adler G, et al. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. J Hepatol 1998; 28:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/42\">",
"      Fleig WE, Kircheis G, Spengler, et al. Placebo-controlled, double-blind evaluation of L-ornithine-L-aspartate (LOLA) granules in patients with cirrhosis and subclinical (SHE) or mild overt hepatic encephalopathy (abstract). J Hepatol 1999; 31(Suppl 2):WP3/1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/43\">",
"      Ong JP, Oehler G, Kr&uuml;ger-Jansen C, et al. Oral L-ornithine-L-aspartate improves health-related quality of life in cirrhotic patients with hepatic encephalopathy: an open-label, prospective, multicentre observational study. Clin Drug Investig 2011; 31:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/44\">",
"      Sushma S, Dasarathy S, Tandon RK, et al. Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial. Hepatology 1992; 16:138.",
"     </a>",
"    </li>",
"    <li>",
"     Ferenci P. Critical evaluation of the role of branched chain amino acids in liver disease. In: Recent Advances in Hepatology, Thomas JC, Jones EA (Eds), Churchill Livingstone, New York 1986. p.137.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/46\">",
"      Naylor CD, O'Rourke K, Detsky AS, Baker JP. Parenteral nutrition with branched-chain amino acids in hepatic encephalopathy. A meta-analysis. Gastroenterology 1989; 97:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/47\">",
"      Als-Nielsen B, Koretz RL, Kjaergard LL, Gluud C. Branched-chain amino acids for hepatic encephalopathy. Cochrane Database Syst Rev 2003; :CD001939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/48\">",
"      Marchesini G, Dioguardi FS, Bianchi GP, et al. Long-term oral branched-chain amino acid treatment in chronic hepatic encephalopathy. A randomized double-blind casein-controlled trial. The Italian Multicenter Study Group. J Hepatol 1990; 11:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/49\">",
"      Horst D, Grace ND, Conn HO, et al. Comparison of dietary protein with an oral, branched chain-enriched amino acid supplement in chronic portal-systemic encephalopathy: a randomized controlled trial. Hepatology 1984; 4:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/50\">",
"      Les I, Doval E, Garc&iacute;a-Mart&iacute;nez R, et al. Effects of branched-chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study. Am J Gastroenterol 2011; 106:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/51\">",
"      Koretz RL, Avenell A, Lipman TO. Nutritional support for liver disease. Cochrane Database Syst Rev 2012; 5:CD008344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/52\">",
"      Basile AS, Harrison PM, Hughes RD, et al. Relationship between plasma benzodiazepine receptor ligand concentrations and severity of hepatic encephalopathy. Hepatology 1994; 19:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/53\">",
"      Basile AS, Hughes RD, Harrison PM, et al. Elevated brain concentrations of 1,4-benzodiazepines in fulminant hepatic failure. N Engl J Med 1991; 325:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/54\">",
"      Basile AS, Jones EA. Ammonia and GABA-ergic neurotransmission: interrelated factors in the pathogenesis of hepatic encephalopathy. Hepatology 1997; 25:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/55\">",
"      Gyr K, Meier R, H&auml;ussler J, et al. Evaluation of the efficacy and safety of flumazenil in the treatment of portal systemic encephalopathy: a double blind, randomised, placebo controlled multicentre study. Gut 1996; 39:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/56\">",
"      Cadranel JF, el Younsi M, Pidoux B, et al. Flumazenil therapy for hepatic encephalopathy in cirrhotic patients: a double-blind pragmatic randomized, placebo study. Eur J Gastroenterol Hepatol 1995; 7:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/57\">",
"      Pomier-Layrargues G, Gigu&egrave;re JF, Lavoie J, et al. Flumazenil in cirrhotic patients in hepatic coma: a randomized double-blind placebo-controlled crossover trial. Hepatology 1994; 19:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/58\">",
"      Van der Rijt CC, Schalm SW, Meulstee J, Stijnen T. Flumazenil therapy for hepatic encephalopathy. A double-blind cross over study. Gastroenterol Clin Biol 1995; 19:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/59\">",
"      Barbaro G, Di Lorenzo G, Soldini M, et al. Flumazenil for hepatic encephalopathy grade III and IVa in patients with cirrhosis: an Italian multicenter double-blind, placebo-controlled, cross-over study. Hepatology 1998; 28:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/60\">",
"      Als-Nielsen B, Kjaergard LL, Gluud C. Benzodiazepine receptor antagonists for acute and chronic hepatic encephalopathy. Cochrane Database Syst Rev 2001; :CD002798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/61\">",
"      Goulenok C, Bernard B, Cadranel JF, et al. Flumazenil vs. placebo in hepatic encephalopathy in patients with cirrhosis: a meta-analysis. Aliment Pharmacol Ther 2002; 16:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/62\">",
"      Loomba V, Pawar G, Dhar KL, Setia MS. Serum zinc levels in hepatic encephalopathy. Indian J Gastroenterol 1995; 14:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/63\">",
"      Ebadi M, Iversen PL, Hao R, et al. Expression and regulation of brain metallothionein. Neurochem Int 1995; 27:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/64\">",
"      Agus ZS, Dukes ID, Morad M. Divalent cations modulate the transient outward current in rat ventricular myocytes. Am J Physiol 1991; 261:C310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/65\">",
"      Marchesini G, Fabbri A, Bianchi G, et al. Zinc supplementation and amino acid-nitrogen metabolism in patients with advanced cirrhosis. Hepatology 1996; 23:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/66\">",
"      Van der Rijt CC, Schalm SW, Schat H, et al. Overt hepatic encephalopathy precipitated by zinc deficiency. Gastroenterology 1991; 100:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/67\">",
"      Riggio O, Ariosto F, Merli M, et al. Short-term oral zinc supplementation does not improve chronic hepatic encephalopathy. Results of a double-blind crossover trial. Dig Dis Sci 1991; 36:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/68\">",
"      C&oacute;rdoba J, Cabrera J, Lataif L, et al. High prevalence of sleep disturbance in cirrhosis. Hepatology 1998; 27:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/69\">",
"      Steindl PE, Finn B, Bendok B, et al. Disruption of the diurnal rhythm of plasma melatonin in cirrhosis. Ann Intern Med 1995; 123:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/70\">",
"      Lewy AJ, Ahmed S, Jackson JM, Sack RL. Melatonin shifts human circadian rhythms according to a phase-response curve. Chronobiol Int 1992; 9:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/71\">",
"      Hearn TJ, Coleman AE, Lai JC, et al. Effect of orally administered L-carnitine on blood ammonia and L-carnitine concentrations in portacaval-shunted rats. Hepatology 1989; 10:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/72\">",
"      Therrien G, Rose C, Butterworth J, Butterworth RF. Protective effect of L-carnitine in ammonia-precipitated encephalopathy in the portacaval shunted rat. Hepatology 1997; 25:551.",
"     </a>",
"    </li>",
"    <li>",
"     Del Olmo JA, Castillo M, Rodrigo JM, et al. Effect of L-carnitine upon ammonia tolerance test in cirrhotic patients. In: Cirrhosis, Hepatic Encephalopathy, and Ammonium Toxicity, Grisolia S (Ed), Plenum Press, New York 1990. p.197.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/74\">",
"      Malaguarnera M, Bella R, Vacante M, et al. Acetyl-L-carnitine reduces depression and improves quality of life in patients with minimal hepatic encephalopathy. Scand J Gastroenterol 2011; 46:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/75\">",
"      Vogels BA, Maas MA, Daalhuisen J, et al. Memantine, a noncompetitive NMDA receptor antagonist improves hyperammonemia-induced encephalopathy and acute hepatic encephalopathy in rats. Hepatology 1997; 25:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/76\">",
"      Yurdaydin C, Herneth AM, P&uuml;sp&ouml;k A, et al. Modulation of hepatic encephalopathy in rats with thioacetamide-induced acute liver failure by serotonin antagonists. Eur J Gastroenterol Hepatol 1996; 8:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/77\">",
"      Yurdaydin C, Li Y, Ha JH, et al. Brain and plasma levels of opioid peptides are altered in rats with thioacetamide-induced fulminant hepatic failure: implications for the treatment of hepatic encephalopathy with opioid antagonists. J Pharmacol Exp Ther 1995; 273:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/78\">",
"      Bajaj JS, Schubert CM, Heuman DM, et al. Persistence of cognitive impairment after resolution of overt hepatic encephalopathy. Gastroenterology 2010; 138:2332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/15/4346/abstract/79\">",
"      Riggio O, Ridola L, Pasquale C, et al. Evidence of persistent cognitive impairment after resolution of overt hepatic encephalopathy. Clin Gastroenterol Hepatol 2011; 9:181.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1255 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-197.136.42.3-965172F715-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_15_4346=[""].join("\n");
var outline_f4_15_4346=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT OF PRECIPITATING CAUSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17167111\">",
"      AGITATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TREATMENTS BASED UPON THE AMMONIA HYPOTHESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Correction of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Reduction in ammoniagenic substrates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Lactulose and lactitol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Enemas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Dietary protein reduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Inhibition of intestinal ammonia production and absorption",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Oral antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Modification of colonic flora (probiotics and prebiotics)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Acarbose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Stimulation of metabolic ammonia metabolism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Ornithine-aspartate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Sodium benzoate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TREATMENTS BASED UPON THE FALSE NEUROTRANSMITTER HYPOTHESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      BCAA infusions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Oral BCAA supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      TREATMENTS BASED UPON THE GABA HYPOTHESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      MISCELLANEOUS TREATMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Zinc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Melatonin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      EXPERIMENTAL TREATMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      L-Carnitine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Glutamatergic antagonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Serotonin antagonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Opioid antagonists",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15422219\">",
"      PROGNOSIS AFTER RECOVERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Acute therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Correction of precipitating causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Lower blood ammonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Chronic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Minimal hepatic encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/1255\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1255|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/9/18589\" title=\"table 1\">",
"      Rx of hepatic encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/50/2860\" title=\"table 2\">",
"      Assessment of Rx in HE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/34/556\" title=\"table 3\">",
"      Precipitants of HE in cirrhosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38538?source=related_link\">",
"      Acute liver failure in adults: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3078?source=related_link\">",
"      Alpha-glucosidase inhibitors and lipase inhibitors for treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11080?source=related_link\">",
"      Benzodiazepine poisoning and withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14200?source=related_link\">",
"      Carnitine metabolism in renal disease and dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/22/34153?source=related_link\">",
"      Clinical manifestations and diagnosis of hepatic encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14506?source=related_link\">",
"      Hepatic encephalopathy: Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/6/6245?source=related_link\">",
"      Hypokalemia-induced renal dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/40/7810?source=related_link\">",
"      Patient information: Hepatic encephalopathy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13034?source=related_link\">",
"      Physiology and clinical use of melatonin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16554?source=related_link\">",
"      Probiotics for gastrointestinal diseases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_15_4347="Factors used to calculate KDPI";
var content_f4_15_4347=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F88376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F88376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Factors used to calculate the kidney donor profile index (KDPI)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Donor age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Donor race/ethnicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypertension in donor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diabetes in donor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Donor height and weight",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Donor serum creatinine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cause of death of donor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HBV or HCV in donor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Donation after cardiac death",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John Vella, MD, FACP, FRCP, FASN.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_15_4347=[""].join("\n");
var outline_f4_15_4347=null;
var title_f4_15_4348="Prevention of barotrauma";
var content_f4_15_4348=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F74558&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F74558&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Prevention of barotrauma and bronchopleural fistula in ventilated patients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Use small tidal volumes (eg, 6 mL/kg predicted body weight or less) in high-risk clinical settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Acute lung injury or acute respiratory distress syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Obstructive lung disease, particularly in the presence of auto-PEEP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Minute ventilation &gt;12 to 15 L/min",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Avoid hyperventilation (ie, arterial PCO2 &lt;40 mmHg), and consider permissive hypercapnia in circumstances listed above, unless contraindicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Use PEEP cautiously in patients at increased risk for alveolar rupture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Acute lung injury or acute respiratory distress syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Obstructive lung disease (eg, COPD, asthma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Unilateral, patchy, or cavitary lung disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Nosocomial pneumonia or sepsis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Monitor static respiratory system compliance as PEEP is applied or increased, and back off on PEEP if compliance falls with increasing levels",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Monitor all ventilated patients for auto-PEEP, and take specific measures to reduce auto-PEEP if its presence could be harmful to the patient:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Normo- or hypercapnia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        High inspiratory flow rate (eg, 70 to 100 L/min)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Low-compressible-volume, low-compliance ventilator circuit",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wean from positive-pressure ventilation as rapidly as possible",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use extreme care in high-risk patients when placing subclavian or internal jugular lines or performing thoracentesis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_15_4348=[""].join("\n");
var outline_f4_15_4348=null;
var title_f4_15_4349="Compare venous arterial grafts";
var content_f4_15_4349=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F61252&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F61252&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparative anatomic and physiological properties of internal mammary artery and saphenous vein grafts",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Property",
"       </td>",
"       <td class=\"subtitle1\">",
"        Internal mammary artery",
"       </td>",
"       <td class=\"subtitle1\">",
"        Saphenous vein",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        Anatomic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Endothelial fenestrations",
"       </td>",
"       <td>",
"        Few",
"       </td>",
"       <td>",
"        Many",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Intercellular (IC) processes",
"       </td>",
"       <td>",
"        Many",
"       </td>",
"       <td>",
"        Few",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        IC junction permeability",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        High",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Internal elastic lamina (IEL)",
"       </td>",
"       <td>",
"        Well defined",
"       </td>",
"       <td>",
"        Poorly defined",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Heparan sulfate in IEL/media",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dependence on vasa vasorum",
"       </td>",
"       <td>",
"        Minimal",
"       </td>",
"       <td>",
"        High",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Valves Absent",
"       </td>",
"       <td>",
"        Present",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Size match with grafted native vessel",
"       </td>",
"       <td>",
"        Good",
"       </td>",
"       <td>",
"        Poor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Resistance to trauma of harvesting",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        Physiologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Flow reserve",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Shear stress",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nitric oxide/prostacyclin production",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vasomotor response to thrombin",
"       </td>",
"       <td>",
"        Relaxation",
"       </td>",
"       <td>",
"        Constriction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vasoconstrictor sensitivity",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        High",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vasodilator sensitivity",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Basic fibroblast growth factor receptors",
"       </td>",
"       <td>",
"        Few",
"       </td>",
"       <td>",
"        Many (8xIMA)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lipolysis",
"       </td>",
"       <td>",
"        Rapid",
"       </td>",
"       <td>",
"        Slow",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lipid synthesis",
"       </td>",
"       <td>",
"        Less active",
"       </td>",
"       <td>",
"        More active",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lipid uptake",
"       </td>",
"       <td>",
"        Slow",
"       </td>",
"       <td>",
"        Rapid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Oxidative stress",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        High",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Motwani JG, Topol EJ. Circulation 1998; 97:916.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_15_4349=[""].join("\n");
var outline_f4_15_4349=null;
var title_f4_15_4350="Dyspnea during pregnancy";
var content_f4_15_4350=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55014&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55014&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dyspnea during pregnancy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 425px; height: 241px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Incidence, time course, and severity of dyspnea during normal pregnancy. Moderate dyspnea increases in frequency from the beginning of the second trimester while severe dyspnea is seen only in the last few weeks of pregnancy (last column).",
"    <div class=\"footnotes\">",
"     NP: not pregnant; blue: dyspnea present climbing hills or more than one flight of stairs; green: dyspnea present on climbing one flight of stairs, walking at an even pace on level ground, or during routine performance of housework; red: dyspnea on slightest exertion or at rest.",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Milne, JA Postgrad Med J 1979; 55:318.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_15_4350=[""].join("\n");
var outline_f4_15_4350=null;
var title_f4_15_4351="Contents: Allergies and asthma";
var content_f4_15_4351=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?18/22/18798\">",
"       Patient Information",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Allergies and asthma",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Allergies and asthma",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Allergies",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/31/41457\">",
"           Patient information: Allergic bronchopulmonary aspergillosis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/8/41092\">",
"           Patient information: Allergic rhinitis (seasonal allergies) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/5/42066\">",
"           Patient information: Allergy shots (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/37/22098\">",
"           Patient information: Allergy to penicillin and related antibiotics (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/3/23603\">",
"           Patient information: Drug allergy (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/38/37474\">",
"           Patient information: Seasonal allergies in adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/10/13475\">",
"           Patient information: Seasonal allergies in children (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/40/5764\">",
"           Patient information: Trigger avoidance in allergic rhinitis (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Allergy tests",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/24/42370\">",
"           Patient information: Allergy skin testing (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Anaphylaxis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/30/33250\">",
"           Patient information: Anaphylaxis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/57/15250\">",
"           Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/14/41186\">",
"           Patient information: Anaphylaxis treatment and prevention (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/31/1523\">",
"           Patient information: Angioedema (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/57/29586\">",
"           Patient information: Epinephrine auto-injectors (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/30/28134\">",
"           Patient information: Use of an epinephrine autoinjector (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Angioedema",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/31/1523\">",
"           Patient information: Angioedema (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Asthma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/20/14660\">",
"           Patient information: Asthma and pregnancy (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/21/18770\">",
"           Patient information: Asthma and pregnancy (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/11/4275\">",
"           Patient information: Asthma in adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/58/17315\">",
"           Patient information: Asthma in children (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/25/29075\">",
"           Patient information: Asthma inhaler techniques in adults (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/3/44083\">",
"           Patient information: Asthma inhaler techniques in children (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/0/37892\">",
"           Patient information: Asthma symptoms and diagnosis in children (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/63/39925\">",
"           Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/60/18374\">",
"           Patient information: Asthma treatment in children (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/2/16419\">",
"           Patient information: Avoiding asthma triggers (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/26/1442\">",
"           Patient information: Exercise-induced asthma (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/6/31841\">",
"           Patient information: How to use a peak flow meter (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/52/13122\">",
"           Patient information: How to use your child���������s dry powder inhaler (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/4/33858\">",
"           Patient information: How to use your child���������s metered dose inhaler (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/47/9970\">",
"           Patient information: How to use your dry powder inhaler (adults) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/34/41506\">",
"           Patient information: How to use your metered dose inhaler (adults) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/43/30386\">",
"           Patient information: Inhalers (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/22/30052\">",
"           Patient information: Medicines for asthma (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/57/37778\">",
"           Patient information: Steroid medicines (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/25/31124\">",
"           Patient information: Trigger avoidance in asthma (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cough",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/0/43011\">",
"           Patient information: Cough in adults (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Dermatitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/38/32354\">",
"           Patient information: Contact dermatitis (including latex dermatitis) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/53/1874\">",
"           Patient information: Dermatitis (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Food allergy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/27/35250\">",
"           Patient information: Food allergy (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/47/29429\">",
"           Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/35/35379\">",
"           Patient information: Food allergy treatment and avoidance (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/35/17971\">",
"           Patient information: Peanut allergy (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hives (urticaria)",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/17/18706\">",
"           Patient information: Chronic hives (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/47/37617\">",
"           Patient information: Hives (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/45/2772\">",
"           Patient information: Hives (urticaria) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/27/44466\">",
"           Patient information: Physical hives (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Insect bites and stings",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/22/18786\">",
"           Patient information: Bee and insect stings (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/44/19138\">",
"           Patient information: Fire ants (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/42/25250\">",
"           Patient information: Insect allergy (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/51/15155\">",
"           Patient information: Insect bites and stings (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/16/10498\">",
"           Patient information: Spider bites (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Nose and sinuses",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/13/37073\">",
"           Patient information: Acute sinusitis (sinus infection) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/8/41092\">",
"           Patient information: Allergic rhinitis (seasonal allergies) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/58/42915\">",
"           Patient information: Chronic rhinosinusitis (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/37/14930\">",
"           Patient information: Chronic sinusitis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/12/11457\">",
"           Patient information: Deviated septum (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/18/29985\">",
"           Patient information: Nasal polyps (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/15/24818\">",
"           Patient information: Nonallergic rhinitis (runny or stuffy nose) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/18/16674\">",
"           Patient information: Rinsing out your nose with salt water (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/38/37474\">",
"           Patient information: Seasonal allergies in adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/10/13475\">",
"           Patient information: Seasonal allergies in children (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/53/17234\">",
"           Patient information: Sinusitis in adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/40/5764\">",
"           Patient information: Trigger avoidance in allergic rhinitis (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-C083DEE3E8-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f4_15_4351=[""].join("\n");
var outline_f4_15_4351=null;
